Analysis of gene regulatory functions of the human acyl-CoA-binding-protein in lipid metabolism by Vock, Christina
Aus dem Institut für Humanernährung und Lebensmittelkunde  
der Christian-Albrechts-Universität zu Kiel 
 
 
 
 
Analysis of Gene Regulatory Functions of the Human 
Acyl-CoA-Binding-Protein in Lipid Metabolism 
 
 
 
 
Dissertation  
zur Erlangung des Doktorgrades  
der Agrar- und Ernährungswissenschaftlichen Fakultät 
 der Christian-Albrechts-Universität zu Kiel 
 
 
 
 
vorgelegt von  
Dipl. troph. Christina Vock 
aus Vacha 
 
 
Kiel, 2008 
 
 
 
 
Dekan: Prof. Dr. U. Latacz-Lohmann 
1.Berichterstatter: Prof. Dr. F. Döring 
2.Berichterstatter: Prof. Dr. G. Rimbach 
Tag der mündlichen Prüfung: 20. 11. 2008 
 
Table of contents 
 1 
Table of contents 
 
Summary………………………………………………………………………………… 2 
Zusammenfassung…………………………………………………………………….. 4 
General Introduction……………………………………………………………........... 6 
General Discussion…………………………………………………………………….. 13 
References……………………………………………………………………………… 20 
Submitted Manuscripts………………………………………………………………… 25 
Summary 
 2 
Summary 
 
The human acyl-CoA binding protein (ACBP) is an ubiquitary expressed 
multifunctional protein. ACBP is localized in the cytosol, nucleus, endoplasmatic 
reticulum and Golgi apparatus. As an intracellular pool former and carrier of acyl-
CoAs, ACBP profoundly influences fatty acid metabolism. ACBP transports acyl-
CoAs to the nucleus and interacts with the transcription factor hepatocyte nuclear 
factor 4 alpha (HNF-4α). The gene encoding ACBP is up-regulated by glucose and 
lipogenic factors and is down-regulated under fasting conditions. Here, the up- and 
down-regulation of the ACBP gene was simulated in liver HepG2 cells by an 
overexpression and RNAi approach to study the gene regulatory function of 
ACBP.  
 
In order to identify ACBP target genes, genome-wide transcript profiling under 
siRNA-mediated ACBP knockdown in human liver HepG2 cells was performed. 
Based on a single sided permutation T-test (p<0.05) 256 down-regulated and 198 
up-regulated transcripts with a minimal fold change of 1.32 (log 0.5) were 
identified. TaqMan-based qRT-PCR of 10 selected genes confirmed high accuracy 
of the array data. Gene annotation enrichment analysis revealed ACBP-mediated 
down-regulation of 18 genes encoding key enzymes in glycerolipid (i.e. 
mitochondrial glycerol-3-phosphate acyltransferase), cholesterol (i.e. HMG-CoA 
synthase 1 and HMG-CoA reductase) and fatty acid (i.e. fatty acid synthase) 
metabolism. Integration of these genes in common pathways suggested a 
decrease of lipid biosynthesis under ACBP knockdown. Accordingly, saturated 
(16:0) and monosaturated (16:1, 18:1) fatty acids were significantly reduced to 
75% in ACBP-depleted cells.  
 
In order to assess the gene regulatory function of ACBP in more detail, reporter 
gene analysis was performed. Using this approach, ACBP repressed the HNF-4α-
induced activity of a 617bp HMGCS1 promoter fragment by about 75% in HepG2 
as well as in non-endodermal HeLa cells devoid of HNF-4α. Interestingly, reporter 
assays without co-transfection of HNF-4α revealed an ACBP-induced reduction of 
HMGCS1 promoter activity by about 60-80% in both cell lines. Activities of 417bp 
and 317bp HMGCS1 promoter fragments were 2-4-fold decreased by ACBP. 
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Concordantly, HMGCS1-mRNA and -protein levels were diminished to about 40% 
and 30% in ACBP-expressing HeLa cells, respectively. Additionally, ACBP 
diminished promoter activity and transcript levels of the cholesterogenic HMGCR.  
 
Taken together, by using the RNAi approach in combination with genome-wide 
expression profiling in HepG2 cells, evidence for the function of human ACBP in 
lipid metabolism at the level of gene expression was obtained. This effect seems 
to be translated to the cellular level of certain fatty acids. An overexpression 
approach suggested an essential function for human ACBP as a transcriptional 
regulator for HMG-CoA synthase 1 and HMG-CoA reductase, encoding the rate-
limiting enzymes of cholesterol synthesis. The 454 identified ACBP-regulated 
genes represent a first reference of the human ACBP-regulon.  
 
Zusammenfassung 
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Zusammenfassung 
 
Das humane Acyl-CoA-Bindungsprotein (ACBP) ist ein ubiquitär exprimiertes und 
multifunktionelles Protein. ACBP ist im Cytosol, im Zellkern, am 
Endoplasmatischen Retikulum sowie am Golgi-Apparat lokalisiert. ACBP dient zur 
Speicherung von zellulären Acyl-CoAs und ist mit dieser Funktion maßgeblich am 
Fettstoffwechsel beteiligt. ACBP transportiert Acyl-CoAs in den Zellkern und 
interagiert mit dem Transkriptionsfaktor Hepatozyten Nukleärer Faktor 4 alpha 
(HNF-4α). Durch Glukose und lipogene Faktoren wird das ACBP-Gen in seiner 
Transkription gesteigert, sowie unter Fasten reprimiert. Diese physiologischen 
Bedingungen sollen in der vorliegenden Arbeit in Zellkulturexperimenten 
nachgestellt werden, um die mögliche Funktion des ACBPs in der Genexpression 
zu untersuchen.  
 
Zur Identifizierung von ACBP-Zielgenen wurden genomweit die Transkriptprofile, 
nach RNAi-vermittelter ACBP-Depletion in humanen HepG2-Zellen, mittels DNA-
Array erfasst. Auf der Basis eines einseitigen Permutations T-Testes (p<0.05) 
konnten 256 herunter- und 198 hoch-regulierte Transkripte, bei einer minimalen 
Veränderung um das 1.32-fache, erfaßt werden. 10 ausgesuchte Transkripte 
wurden durch quantitative RT-PCR nach dem TaqMan-Prinzip verifiziert. Die 
Ergebnisse bestätigen die hohe Genauigkeit der Array-Daten. Eine Gen-
Annotations-Anreicherungs-Analyse sowie eine funktionelle Allokation der ACBP-
sensitiven Gene führten zur Identifizierung von 18 reprimierten Genen. Diese 
kodieren Schlüsselenzyme der Glyzerolipid- (z.B. mitochondrielle Glyzerol -3-
Phosphat Acyltransferase), der Cholesterol- (z.B. HMG-CoA Synthase 1, HMG-
CoA Reduktase) und Fettsäure- (z.B. Fettsäure-Synthase) -Synthese. Auf 
Metabolitebene führte die ACBP-Depletion in HepG2-Zellen zu einer signifikanten 
Erniedrigung der gesättigten C16:0, der einfach ungesättigten C16:1 und der 
C18:1 Fettsäuren um 25%. 
 
Zur weiteren Untersuchung der genregulatorischen Funktion des ACBPs wurden 
Reporter-Gen-Analysen in HepG2-Zellen und HeLa-Zellen, die kein HNF-4α 
exprimieren, durchgeführt. In beiden Zelllinien konnte gezeigt werden, dass die 
ACBP-Überexpression die HNF-4α induzierte Aktivität eines 617bp HMGCS1 
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Promotorfragmentes um 75% vermindert. Interessanterweise ist diese 
Unterdrückung nicht von der Überexpression des HNF-4α abhängig. Die Aktivität 
von zwei kürzeren HMGCS1 Promotorfragmenten wird durch ACBP-Expression 
ebenfalls um das 2-4-fache reduziert. Darüber hinaus führt die ACBP-
Überexpression in HeLa-Zellen zur Erniedrigung der HMGCS1 mRNA- bzw. 
Protein-Spiegel um 40% bzw. 30%. Die HMGCR wird ebenfalls auf Promotor- und 
mRNA Ebene unter ACBP-Überexpression reprimiert. 
 
In dieser Arbeit wurde erstmals gezeigt, dass ACBP zentrale Gene des Lipid- und 
Cholesterinstoffwechsels auf Ebene der Genexpression reguliert und dass dieser 
Effekt teilweise auf Metabolitebene abbildbar ist. Durch ACBP-Überexpression 
konnte die wesentliche Bedeutung des humanen ACBPs als transkriptioneller 
Regulator der HMG-CoA synthase 1 und der HMG-CoA Reduktase zusätzlich 
bestätigt werden. Mit der Identifizierung von 454 ACBP-sensitiven Genen ist es 
schließlich gelungen eine erste Version des humanen ACBP-Regulons zu 
erstellen. 
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General Introduction 
 
Nutrigenomics is a new field in nutritional science focusing on the molecular 
relationship between diet and the human genome. Post-genomic technologies are 
used to assess gene expression level (transcriptomics), protein level (proteomics) 
as well as metabolites (metabolomics) as a function of different nutrients. With 
these approaches, beneficial and/ or detrimental effects of food components on 
health and disease were studied to a certain extent during the last years (1-4). In 
this context, the multifunctional human acyl-CoA binding protein (ACBP) was 
identified as a candidate gene for psychiatric disorders and the metabolic 
syndrome. ACBP controls the intracellular concentration of fatty acids contributing 
to the development of insulin resistance. The gene encoding ACBP is up-regulated 
by glucose and lipogenic factors and down-regulated under fasting conditions. In 
the following, the up- and down-regulation of the ACBP gene was simulated in 
liver HepG2 cells by an overexpression and RNAi approach in order to study the 
gene regulatory function of ACBP. 
 
Mogensen et al. (1987) have firstly described the existence of ACBP (5). After the 
purification of this small 10 kDa protein from bovine liver a vast amount of work 
was done describing its cellular function. However, the exact role of ACBP is still 
not fully understood. Several synonyms are actually used for ACBP, indicating the 
functional versatility of this ubiquitary expressed and highly conserved protein. 
Firstly, ACBP was described as diazepam binding inhibitor (DBI) or endozepine 
(EP) according to its ability to displace the anxiolytic drug diazepam or valium from 
the benzodiazepine recognition site of gamma-aminobutyric acid (GABA) receptor 
in rat brain (6). Thereinafter, a protein from porcine intestine was isolated that 
specifically stimulated cholecystokinin release and thus pancreatic enzyme 
secretion. Accordingly, Herzig et al. (1996) named it cholecystokinin-releasing 
peptide (CCK-RP). This peptide however was identical to the porcine DBI (7). The 
common name ACBP came up as binding studies verified sequestering of acyl-
CoAs with very high affinity (KD=1-5nM) (8). 
 
ACBP belongs to a group of lipid binding proteins harboring also fatty acid binding 
protein (FABP) and sterol carrier protein (SCP). ACBP exerts high affinity towards 
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long-chain fatty acid coenzyme A esters (acyl-CoA) and low affinity towards the 
shorter acetyl- and butyryl-CoAs. Free fatty acids and cholesterol are not bound by 
ACBP (8-10). The high affinity to sequester acyl-CoAs depends on various 
structural features of ACBP (Fig. 1). Nuclear magnetic resonance spectroscopy 
displayed 4 α-helices in up-down-down-up orientation (11-14). Studies with ACBP/ 
palmitoyl-CoA complexes showed subdivision of the ligand binding sites into one 
for the adenine ring, one for the 3’-phosphate and one for the palmitoyl part of the 
ligand. The adenine moiety is bound into a hydrophobic pocket formed by the 
aromatic ring of tyrosine at position 31. The 3’-phosphate group interacts strongly 
with the protein through hydrogen bounds belonging to tyrosin at position 28 and 
lysine at position 32 and 54, making up 40% of the total binding energy. The 
orientation of the ligand is profoundly determined by pantetheine and cysteamine 
residues. Beside ACBP, mouse endozepine-like peptide (ELP) (15), membrane-
associated (MA)-DBI (16) and DBI-related sequence 1 (DRS-1) (17) also possess 
the acyl-CoA binding domain. Recently, a crystallization study revealed a novel 
dimeric mode of ligand binding for human ACBP. Thus, the acyl-CoA moiety is 
positioned across two ACBP molecules what may enable them to flip-out (18).  
 
 
 
Fig. 1 3D model of bovine ACBP in complex with palmitoyl-CoA 
The model is based on NMR structure established by Kragelund et al. (2003) (11) 
and was adopted from NCBI Structure database.  
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The ACBP gene is located on chromosome 2q12-q21, whereas an inoperable 
ACBP-related pseudogene is localized on chromosome 6 (19). Computational 
promoter analysis classified ACBP as a typical housekeeping gene (20). So far, 
three transcripts encoding for polypeptides of 86, 88 and 104 amino acids were 
identified (21,22). The three ACBP isoforms differ within their N-terminal amino 
acid residues and arise from alternative usage of the first exon. Most functional 
work however was done on the ACBP of 86 amino acid residues. ACBP is 
ubiquitary expressed with highest abundance in tissues of elevated energy 
requirement as in steroid-producing cells of adrenal cortex or testis and in 
epithelial cells responsible for secretion or water transport (23). At the cellular 
level, microscopy revealed distribution of ACBP in the cytosol, nucleus (24), 
endoplasmatic reticulum (ER) and Golgi (25). 
 
The broad abundance of ACBP from yeast to mammals may indicate essentiality 
of this small protein. Concordantly, ACBP depletion in the parasite Trypanosoma 
brucei was lethal (26). Less severely, Acb1p (the yeast ACBP homologue) 
exhausted yeast were growth retarded and showed perturbed membrane 
assembly, organization and structure (27,28). Experimental cell culture data were 
rather contradictory (29-31). The loss of ACBP in mouse was not lethal but hair 
lipid profile and hair appearance were altered, with sparse, matted hair with greasy 
appearance (32). 
 
In mammals, ACBP regulates highly specific processes depending mainly on cell 
and tissue type (Fig. 2). Interestingly, ACBP might control glucose homeostasis. 
The occurrence in glucagon-producing A cells of the endocrine pancreas 
suggested a paracrine interaction of ACBP with insulin secretion. Indeed, in vitro 
perfusion studies from rat pancreas (33) and isolated rat islets (34) have shown a 
moderate inhibitory effect of ACBP on glucose-induced insulin secretion. 
Inconsistently, in vivo administration of ACBP could not reconstitute the in vitro 
conditions (35). Thus, the impact of ACBP on insulin secretion is still under 
discussion. ACBP expression in brain is functionally linked with behavioral 
disorders. Binding of ACBP and its processing products triakontatetraneuropeptide 
(TTN) and octadecaneuropetide (ODN) to GABA-receptor as well as the synthesis 
of neuroactive steroids act neuromodulatory (36). The administration of these 
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peptides initiated pro-conflict behavior in rats (37,38). In humans, ACBP level were 
increased in patients with severe anxiety and epilepsy (39). Data concerning 
Alzheimer disease are conflicting (40,41). Thus, ACBP was regarded as a 
candidate gene for anxiety disorders. A single nucleotide polymorphism (SNP) at 
position 88 leading to an amino acid change (valine to methionine) was associated 
with anxiety mediated panic attacks (42). Moreover, external stimuli such as 
nicotine (43) and alcohol (44) induced ACBP-mRNA expression in mouse brain 
after long-term administration and thus might promote behavioral changes. In 
addition, hippocampus-dependent learning was impaired in ACBP transgenic mice 
(45).  
 
In steroidogenic cells and tissues, ACBP and its proteolytic peptides are involved 
in cholesterol metabolism since their administration stimulated mitochondrial 
cholesterol uptake and subsequent steroid hormone synthesis (46,47). The 
interaction of ACBP with peripheral benzodiazepine receptor (PBR) or 18 kDa 
translocator protein is decisive for this function (48). ACBP is also involved in cell 
proliferation (49), bacterial defense (50), apoptosis (30,51) and inflammation 
(52,53). Beside these highly specific functions, its role in fatty acid metabolism was 
predominantly in focus of former work. The induction of medium-chain fatty acid 
synthesis by ACBP (5) established the importance of this protein in general lipid 
metabolism.  
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Fig. 2 Functions of ACBP at different levels of biological complexity 
ACBP binds and transports acyl-CoAs towards metabolizing enzyme systems for 
energy production but also for the synthesis of complex lipids. Enzymes, ion 
channels and signal transduction pathways are also protected against acyl-CoAs 
detergenic effects. Because ACBP is also nuclear localized it might directly or 
indirectly affect gene expression. ACBP exerts highly specialized functions 
dependent on cell and tissue type. At physiological level, ACBP fulfils versatile 
functions contributing to certain pathophysiological conditions.  
ACC, acetyl-CoA carboxylase; ACS, acyl-CoA synthetase; ANT, adenine nucleotide translocase; 
CE, cholesteryl ester; GABA, gamma-aminobutyric acid; HNF-4α, hepatocyte nuclear factor 4α; 
PBR, peripheral benzodiazepine receptor 
 
 
Compelling evidence that ACBP participates in acyl-CoA transport and pool 
formation was obtained from various in vivo and in vitro studies. In vivo studies in 
yeast expressing bovine or yeast ACBP (54,55) showed higher levels of acyl-
CoAs. Moreover, overexpression of Acb1p changed acyl-CoA composition 
profoundly with an accumulation of C16:0-CoA and a reduction of C18:0- and 
C18:1-CoA (55). Concordantly, acyl-CoA composition in Acb1p knockout yeast 
was shifted towards C18:0-CoA enrichment and C26:0-CoA reduction (27). Similar 
to yeast, total acyl-CoA pool did rise in ACBP transgenic mice and rats. Data 
according acyl-CoA composition are rather conflicting (56,57). Accumulation 
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seems however to be specific to the membrane/ microsomal pool (56). The 
changes observed in acyl-CoA composition and length in yeast as well as in 
rodents further strengthen the role of ACBP in termination of fatty acid synthesis 
and transport of the former towards the elongation system. In vitro, the presence 
of ACBP attenuated the inhibitory effect of long-chain acyl-CoAs on long-chain 
acyl-CoA carboxylase (ACC) and adenine nucleotide translocase (ANT). Both 
enzymes are rate-limiting in energy metabolism. Additionally, ACBP protects acyl-
CoAs against hydrolyses by microsomal acyl-CoA hydrolase and stimulates 
mitochondrial long-chain acyl-CoA synthetase (58,59). This might additionally 
contribute to the enlargement of the acyl-CoA pool in various overexpression 
approaches.  
 
Binding and transport of acyl-CoAs by ACBP essentially affects the biological 
function and utilization of acyl-CoA esters. Especially in vitro data support the 
ability of ACBP to transfer acyl-CoAs between membranes. This affects the activity 
of membrane-bound enzymes and leads to the desorption and donation of acyl-
CoAs (60). Mitochondrial carnitine palmitoyltransferase (CPT) I enzyme activity 
correlated with the concentration of ACBP-bound acyl-CoA and was therefore 
proposed to interact directly with the ACBP/ acyl-CoA-complex (61). Moreover, 
ACBP donates acyl-CoAs to various transacylation systems, thereby also 
changing enzyme activity. This was described for the acyl-CoA:lysophospholipid 
acyltransferase (LAT) (62) or acyl-CoA:cholesterol acyltransferase (63).  
 
Acyl-CoAs are important intermediates for lipid metabolism as well as for signaling 
pathways. The availability of acyl-CoAs is also dependent on the nutritional status 
of a cell. ACBP protein levels are elevated under the administration of a high fat 
diet and diminished under a fasting regime (64). Although acyl-CoAs rise under 
both conditions, ACBP levels behave opposing. Thus, under a high fat diet ACBP 
redistributes acyl-CoAs away from the mitochondrial membrane towards the ER 
for triacylglyceride synthesis, whereas under fasting conditions ACBP levels 
decline in order to increase acyl-CoA availability for ß-oxidation. Hence, ACBP 
expression is regulated by lipo-oxidative peroxisome proliferator-activated receptor 
(PPAR) (65) as well as lipogenic sterol regulatory element-binding protein 
(SREBP) (66,67). Both transcription factors are key-regulators of genes involved in 
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lipid metabolism. Dual regulation of the ACBP gene through PPAR and SREBP 
establishes further ACBPs role as acyl-CoA donor and carrier (67,68). The 
expression of ACBP is also modulated by hormones, such as androgens (69,70) 
or insulin (71). 
 
Since ACBP is nuclear localized (24) and was shown to interact with hepatocyte 
nuclear factor (HNF)-4α (72), it is assumed that ACBP might also possess a gene 
regulatory function. Moreover, the nuclear transport and abundance of acyl-CoAs 
might impact the activity of various transcription regulators such PPAR, HNF-4α or 
the thyroid hormone receptor (TR) (73,74). In Acb1p knockout yeast, transcript 
profiling revealed a putative gene regulatory function of ACBP. The aim of the 
current work was to gain insight into ACBPs gene regulatory function in human 
cells. As first approach, RNAi-mediated ACBP knockdown was employed in liver 
HepG2 cells in order to identify and characterize ACBP target genes.  
 
 
Chapter I 
 C. Vock, K. Biedasek, I. Boomgaarden, A. Heins, I. Nitz, F. Döring: 
“ACBP knockdown leads to down-regulation of genes encoding rate-limiting 
enzymes in cholesterol and fatty acid metabolism“. submitted in Physiological 
Genomics 
 
In our second approach we analyzed the putative gene regulatory function of 
ACBP in the cholesterol biosynthesis pathway. Thus, by applying ACBP 
overexpression in liver HepG2 and cervical HeLa cells, we investigated the role of 
ACBP in the transcriptional regulation of HMG-CoA synthase 1 and HMG-CoA 
reductase genes. Both genes encode rate-limiting enzymes of cholesterol 
synthesis.  
 
Chapter II 
 C. Vock, F.Döring, I. Nitz: “Regulation of the rate-limiting cholesterogenic 
enzymes HMG-CoA synthase and HMG-CoA reductase by human ACBP”. 
Cell Physiol Biochem. 2008;22(5-6):515-24 
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General Discussion 
 
ACBP was initially classified as a typical housekeeping gene (20). Later studies 
revealed, that ACBP is regulated by nutritional status (64), hormones (71,75) and 
lipogenic transcription factors (65,67). Since ACBP controls the intracellular fate of 
fatty acids and acyl-CoAs, it was described as a candidate gene for diabetes type 
2 (76). ACBPs nuclear localization (24) and its role in the nuclear delivery of acyl-
CoAs gave rise to the assumption that ACBP might also possess a gene 
regulatory function. Supportively, ACBP interacts with HNF-4α (72), a nuclear 
factor controlling genes of glucose and fatty acid metabolism. The present work 
aimed to unravel the gene regulatory function of ACBP and to identify putative 
ACBP target genes.  
 
In order to identify ACBP target genes, a combined approach of ACBP knockdown 
by RNA interference and gene expression profiling by microarray technology was 
employed in liver HepG2 cells (Chapter I). The reliability for siRNA mediated gene 
knockdown for gene function analysis was approved by De Souza et al. (77), since 
transcript profiles after siRNA mediated PPARα depletion in hepatocytes were 
highly comparable to those of PPARα knockout mice. Transfection of an ACBP 
specific siRNA efficiently reduced cellular ACBP protein levels to 20% in liver 
HepG2 cells. The degree of knockdown was comparable to other studies (78-80) 
and was not accompanied by pleitrophic effects (cytotoxicity and/ or apoptosis). 
Till today the essentiality of ACBP is questionable. Target disruption of ACBP in 
the parasite Trypanosoma brucei is lethal (26) and yeast exhausted in Acb1p (the 
ACBP homologue) are growth-retarded (27). A mutation within the ACBP locus in 
mice resulted in sparse hair, male infertility, failure to thrive, hydrocephaly and 
anemia (81). Results from in vivo cell culture experiments seem to be conflicting. 
We alike others did not find impaired viability of ACBP-exhausted cells. In contrast, 
Faergeman et al. (82) observed severe cell death after ACBP depletion. 
Knockdown efficiency might partly explain divergent results obtained from cell 
culture experiments. In this study a 80% reduction of the ACBP protein was 
achieved. Other studies reported a complete depletion of ACBP.  
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In this study, a homogenous cell population cultured under standardized 
conditions was used in order to identify ACBP target genes. 454 differential 
regulated genes with a minimal fold change of 1.32 were identified under ACBP 
knockdown. The selected threshold of 1.32 indicates rather subtle changes of 
transcript abundance but may facilitate the identification of physiological networks. 
In comparison, pharmaceutical agents lead to drastic effects on the transcriptome 
because of high specificity and affinity on biological targets (83). Hence, data from 
the current study might be more comparable to effects achieved by nutritional 
interventions and thus physiological conditions. Nevertheless, fold changes in 
transcript levels assessed by microarray were verified by qRT-PCR.  
 
According to ACBPs function in fatty acid and acyl-CoA metabolism, gene 
annotation enrichment analysis revealed 22 ACBP-regulated genes allocating to 
cellular lipid metabolism. The vast amount of these genes was transcriptionally 
repressed and could be classified to fatty acid, glycerolipid and cholesterol 
synthesis. Thus, depletion of the lipid binding protein ACBP promotes 
transcriptional repression of genes encoding rate-limiting lipogenic enzymes. 
ACBP knockdown leads to a down-regulation of fatty acid synthase (FASN), 
ELOVL family member 6 (ELOVL6) and peroxisomal trans 2-enoyl CoA reductase 
(PECR). FASN is the rate-limiting enzyme of fatty acid synthesis since it 
possesses all enzymatic activities required for each cycle of fatty acid chain 
synthesis towards palmitic acid. ELOVL and PECR are both involved in fatty acid 
elongation. In accordance to gene expression data, the levels of saturated fatty 
acid C16:0 and the monounsaturated fatty acids C16:1 and C18:1 were reduced 
under ACBP knockdown. It should be mentioned, that the translation of expression 
profiles into metabolites is not always assured (84). 
 
Consistent with disturbed phospholipid metabolism observed in Acb1p knockout 
yeast (85), mitochondrial glycerol-3-phosphate acyltransferase (GPAM) was down-
regulated in our study. GPAM encodes the acylation of glycerol-3-phosphate to 
lysophosphatic acid. Moreover, cellular depletion of ACBP repressed four 
cholesterogenic genes, including HMG-CoA synthase (HMGCS1) and HMG-CoA 
reductase (HMGCR), encoding the rate-limiting enzymes of cholesterol synthesis. 
Additionally, the more down-stream acting isopentenyl-diphosphate delta 
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isomerase 1 (IDI1) and lanosterol synthase (LSS) were transcriptionally repressed. 
Therefore, only certain genes of the cholesterol biosynthesis pathway are 
differential expressed under ACBP knockdown. This phenomenon was also 
observed by others (84). Former studies already showed the implementation of 
ACBP in cholesterol metabolism for steroidogenic tissues (47,86). A putative gene 
regulatory role for ACBP in cholesterol synthesis was not yet described. 
Accordingly, the role of ACBP in the transcriptional control of HMGCS1 and 
HMGCR was investigated in a more comprehensive way (Chapter II). Expression 
of ACBP strongly suppressed HMGCS1 and HMGCR promoter activity in HepG2 
and cervical HeLa cells. Moreover, HMGCS1 and HMGCR transcript levels were 
repressed in HeLa cells. As HMGCS1 protein was only moderately reduced by 
ACBP expression, cellular cholesterol levels were not significantly changed under 
the experimental set-up used. This might also reflect complex regulation of 
cholesterol biosynthesis not only at the transcriptional level but also through 
negative feedback control or by post-transcriptional mechanisms (87).  
 
ACBP overexpression leads to a decreased expression of HMGCS1 and HMGCR 
but cellular cholesterol levels were not affected in our experimental set-up using 
cervical HeLa cells. In steroidogenic tissues, altered cellular ACBP level may 
affect steroid hormone synthesis by substrate deficiency. Modified ACBP level 
may also influence the steroidogenesis via the PBR signaling pathway (88). 
Additionally, changed ACBP level might impact the hydrophobic environment of 
the mitochondrial membrane and hence cholesterol uptake (89). Infertility of ACBP 
knockout mice in vivo support the profound function of ACBP in steroidogenesis 
(32). 
 
In general, attenuated cholesterol build-up might impair membrane synthesis and 
structure. Recent studies have already shown fragmented vacuoles in yeast 
lacking the cholesterol equivalent ergosterol (90). Supportively, aberrant 
membrane structures and vesicle accumulation were observed in Acb1p knockout 
yeast (28). Gene expression profiling in these yeast cells showed a repression of 
the cytochrome P450 lanosterol 14a-demethylase which participates in the 
ergosterol biosynthesis pathway (85). In accordance, an altered fatty acid 
composition under ACBP knockdown was found in this study (Chapter I). Similar 
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results were also reported by others (82). In transgenic animals plasma (57) and 
tissue (56) cholesterol levels were not changed and likewise membrane 
disturbances were not observed in a yeast ACBP overexpression approach (54). 
Plasma membranes are crucial for the exchange of nutrients, metabolites and 
signal transduction. The lipid raft hypothesis (91) further strengthens the role of 
cholesterol for membrane organization and vesicular processes. Lipid rafts are 
special sphingolipid- and cholesterol-rich microdomains containing a variety of 
signaling and transport proteins as well as signaling lipids. Cholesterol has been 
proposed to be the basic element for raft formation (92). Thus, ACBP depletion 
might also have an impact on transduction of signals or cellular nutrient uptake.  
 
The obtained data (Chapter I & II) implicate a key role for human ACBP in 
cholesterol synthesis at the level of gene expression. Unexpectedly, HMGCS1 and 
HMGCR were transcriptional repressed under ACBP knockdown and 
overexpression of ACBP. Thus, a transcription factor function of ACBP does not 
seem very presumable, although the protein is nuclear localized (24). This was 
supported by chromatin immunoprecipitation since binding of ACBP towards 
genomic sites of the HMGCS1 promoter was not observed (Chapter II). In general, 
an orchestra of transcription factors act together in controlling transcription, not 
only by direct DNA binding but also by co-factor recruitment acting as co-activators 
or co-repressors (reviewed in (93)). Physical interaction of ACBP with the 
transcription factor HNF-4α was shown to transactivate an apolipoprotein B (ApoB) 
promoter construct. Additionally, HNF-4α activates a wide variety of genes, 
including those involved in cholesterol, fatty acid and glucose metabolism (94). 
However, ACBP suppressed the promoter activity of HMGCS1 and HMGCR in 
endodermal HeLa cells devoid of HNF-4α (95). Based on these findings, we 
propose a co-factor function of ACBP in gene expression. Beside HNF-4, other 
transcription factor may interact with ACBP. Sterol regulatory element-binding 
protein (SREBP)-2 activates cholesterogenic genes under sterol-deprivation and 
decreases expression to basal levels in the presence of cholesterol (87). Hence, 
SREBP-2 is the principle regulator of cholesterol synthesis and might also interact 
with ACBP. This has to be approved in ongoing studies but in initial experiments 
co-transfection of SREBP-2 in HeLa cells could not abolish ACBPs repressive 
effect on basal HMGCS1 promoter activity. 
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Synergistic and/ or allosteric transcriptional control could be mechanisms to 
explain similar effects on gene expression by ACBP overexpression and ACBP 
knockdown. Depending on co-factor recruitment an activator could switch to 
become a repressor (96). Regarding ACBPs proposed co-factor function, its 
expression level may influence the recruitment of transcription factors, which may 
increase or decrease gene transcription. Post-translational modification of ACBP 
may also effect expression of target genes. It has been shown, that stress-induced 
phosphorylation of ACBP leads to trafficking of the protein from the nucleus to the 
cytosol (97). A shift in cellular fatty acid and/ or fatty acid derivatives could also be 
implicated in transcriptional suppression of cholesterol biosynthesis since these 
metabolites are involved in signal transduction and gene expression (59). In this 
regard, ACBP influences the balance between the levels of fatty acids and acyl-
CoA esters (Chapter I). Total fatty acid content behaves proportional to cellular 
ACBP levels, whereas acyl-CoAs levels, especially of stearate-CoA, increased 
both under ACBP depletion and overexpression (27,56). 
 
As shown recently, transcriptional changes in Acb1p depleted yeast were not 
complementable by a yeast mutant unable to bind acyl-CoA esters (85). The 
ACBP/ acyl-CoA complex or the ability of ACBP to donate acyl-CoAs towards the 
nucleus might modulate gene expression. Acyl-CoAs agonize and antagonize 
several nuclear factors (74,98). For example, acyl-CoAs activate HNF-4α under 
concurrent inhibition of PPARα transcriptional activity (99). Also thyroid hormone 
receptor (TR) interacts with acyl-CoA esters (73). Especially, acyl-CoA chain 
length and degree of saturation influence the preference of transcription factors for 
ligand binding (100). Fatty acid level and composition were modified in various 
experimental setups (Chapter I) (28,56). PPARα, retinoid X receptor (RXR)-α or 
liver X receptor (LXR)-α are directly activated by fatty acids whereas SREBP1c 
and nuclear factor κB (NF-κB) are regulated by indirect mechanisms (reviewed by 
(74)). The cross-talk between various nuclear factors including also transcription 
factor displacement from the promoter might be an additional regulatory 
determinant (101).  
The proposed gene regulatory mechanisms of ACBP are summarized in Fig. 3. In 
sum, many studies describe opposing results on target gene expression after co-
factor depletion and overexpression (102,103) whereas others did not (104). The 
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rationale for transcriptional suppression of HMGCS1 and HMGCR after ACBP 
depletion and overexpression is not clear but could be explained by a co-factor 
function of ACBP.  
 
 
 
Fig. 3 Putative gene regulatory mechanisms of human ACBP 
The cellular ACBP levels are modulated by nutritional regimes and hormones. This 
could affect the gene regulatory function of ACBP. Different modes of gene 
regulation by ACBP are possible. In an indirect way, ACBP level might modify the 
availability of specific hydrophobic-ligands for nuclear factors (e.g. FA & acyl-CoA). 
In a more direct manner, ACBP might act via protein-protein interaction as 
transcriptional co-factor.  
 
 
In this study, an isolated cell culture model was used in order to unravel the gene 
regulatory function of ACBP. It should be mentioned, that cell cultures are artificial 
systems and obtained results have to be verified in more complex setups. On the 
other hand, cell culture systems are more feasible to study basic gene function 
under highly standardized conditions. Cell culture studies are also usable for future 
approaches, in order to anticipate the impact of special dietary factors (e.g. 
different fatty acids) on the gene regulatory function of ACBP. The 454 identified 
ACBP regulated genes represent a first reference of the human ACBP regulon. 
General Discussion 
 19 
This will substantially facilitate the understanding of ACBPs cellular function also in 
regard to its role as a disease-related candidate gene. 
 
References 
 20 
References 
 
1. de Wilde, J., Mohren, R., van den Berg, S., Boekschoten, M., Dijk, K. W., 
de Groot, P., Muller, M., Mariman, E., and Smit, E. (2008) Physiol 
Genomics 32(3), 360-369 
2. Lau, F. C., Bagchi, M., Sen, C. K., and Bagchi, D. (2008) Mol Cell Biochem  
3. Walsh, M. C., Brennan, L., Pujos-Guillot, E., Sebedio, J. L., Scalbert, A., 
Fagan, A., Higgins, D. G., and Gibney, M. J. (2007) Am J Clin Nutr 86(6), 
1687-1693 
4. Thalacker-Mercer, A. E., Fleet, J. C., Craig, B. A., Carnell, N. S., and 
Campbell, W. W. (2007) Am J Clin Nutr 85(5), 1344-1352 
5. Mogensen, I. B., Schulenberg, H., Hansen, H. O., Spener, F., and Knudsen, 
J. (1987) Biochem J 241(1), 189-192 
6. Guidotti, A., Forchetti, C. M., Corda, M. G., Konkel, D., Bennett, C. D., and 
Costa, E. (1983) Proc Natl Acad Sci U S A 80(11), 3531-3535 
7. Herzig, K. H., Schon, I., Tatemoto, K., Ohe, Y., Li, Y., Folsch, U. R., and 
Owyang, C. (1996) Proceedings of the National Academy of Sciences of 
the United States of America 93(24), 14214-14214 
8. Mikkelsen, J., and Knudsen, J. (1987) Biochem J 248(3), 709-714 
9. Knudsen, J., Hojrup, P., Hansen, H. O., Hansen, H. F., and Roepstorff, P. 
(1989) Biochem J 262(2), 513-519 
10. Rosendal, J., Ertbjerg, P., and Knudsen, J. (1993) Biochem J 290 (Pt 2), 
321-326 
11. Kragelund, B. B., Andersen, K. V., Madsen, J. C., Knudsen, J., and 
Poulsen, F. M. (1993) J Mol Biol 230(4), 1260-1277 
12. Andersen, K. V., Ludvigsen, S., Mandrup, S., Knudsen, J., and Poulsen, F. 
M. (1991) Biochemistry 30(44), 10654-10663 
13. Andersen, K. V., and Poulsen, F. M. (1992) Journal of Molecular Biology 
226(4), 1131-1141 
14. Kragelund, B. B., Knudsen, J., and Poulsen, F. M. (1999) Biochimica et 
Biophysica Acta-Molecular and Cell Biology of Lipids 1441(2-3), 150-161 
15. Pusch, W., Balvers, M., Hunt, N., and Ivell, R. (1996) Mol Cell Endocrinol 
122(1), 69-80 
16. Todaro, G. J., Rose, T. M., and Shoyab, M. (1991) Neuropharmacology 
30(12B), 1373-& 
17. Suk, K., Kim, Y. H., Hwang, D. Y., Ihm, S. H., Yoo, H. J., and Lee, M. S. 
(1999) Biochimica et Biophysica Acta-Molecular Basis of Disease 1454(1), 
126-131 
18. Taskinen, J. P., van Aalten, D. M., Knudsen, J., and Wierenga, R. K. (2007) 
Proteins 66(1), 229-238 
19. Gersuk, V. H., Rose, T. M., and Todaro, G. J. (1995) Genomics 25(2), 469-
476 
20. Mandrup, S., Hummel, R., Ravn, S., Jensen, G., Andreasen, P. H., 
Gregersen, N., Knudsen, J., and Kristiansen, K. (1992) Journal of Molecular 
Biology 228(3), 1011-1022 
21. Kolmer, M., Rovio, A., and Alho, H. (1995) Biochemical Journal 306, 327-
330 
22. Nitz, I., Doring, F., Schrezenmeir, J., and Burwinkel, B. (2005) Int J 
Biochem Cell Biol 37(11), 2395-2405 
References 
 21 
23. Knudsen, J., Jensen, M. V., Hansen, J. K., Faergeman, N. J., Neergaard, T. 
B. F., and Gaigg, B. (1999) Molecular and Cellular Biochemistry 192(1-2), 
95-103 
24. Elholm, M., Garras, A., Neve, S., Tornehave, D., Lund, T. B., Skorve, J., 
Flatmark, T., Kristiansen, K., and Berge, R. K. (2000) Journal of Lipid 
Research 41(4), 538-545 
25. Hansen, J. S., Faergeman, N. J., Kagelund, B. B., and Knudsen, J. (2007) 
Biochem J  
26. Milne, K. G., Guther, M. L., and Ferguson, M. A. (2001) Mol Biochem 
Parasitol 112(2), 301-304 
27. Schjerling, C. K., Hummel, R., Hansen, J. R., Borsting, C., Mikkelsen, J. M., 
Kristiansen, K., and Knudsen, J. (1996) J Biol Chem 271(37), 22514-22521 
28. Gaigg, B., Neergaard, T. B. F., Schneiter, R., Hansen, J. K., Faergeman, N. 
J., Jensen, N. A., Andersen, J. R., Friis, J., Sandhoff, R., Schroder, H. D., 
and Knudsen, J. (2001) Molecular Biology of the Cell 12(4), 1147-1160 
29. Faergeman, N. J., and Knudsen, J. (2002) Biochem J 368(Pt 3), 679-682 
30. Shulga, N., and Pastorino, J. G. (2006) J Biol Chem 281(41), 30824-30833 
31. Mandrup, S., Sorensen, R. V., Helledie, T., Nohr, J., Baldursson, T., Gram, 
C., Knudsen, J., and Kristiansen, K. (1998) Journal of Biological Chemistry 
273(37), 23897-23903 
32. Lee, L., DeBono, C. A., Campagna, D. R., Young, D. C., Moody, D. B., and 
Fleming, M. D. (2007) J Invest Dermatol 127(1), 16-23 
33. Chen, Z. W., Agerberth, B., Gell, K., Andersson, M., Mutt, V., Ostenson, C. 
G., Efendic, S., Barrossoderling, J., Persson, B., and Jornvall, H. (1988) 
European Journal of Biochemistry 174(2), 239-245 
34. Ostenson, C. G., Ahren, B., Karlsson, S., Sandberg, E., and Efendic, S. 
(1990) Regulatory Peptides 29(2-3), 143-151 
35. Ostenson, C. G., Ahren, B., Johansson, O., Karlsson, S., Hilliges, M., and 
Efendic, S. (1991) Neuropharmacology 30(12B), 1391-& 
36. Costa, E., and Guidotti, A. (1991) Life Sci 49(5), 325-344 
37. Slobodyansky, E., Guidotti, A., Wambebe, C., Berkovich, A., and Costa, E. 
(1989) J Neurochem 53(4), 1276-1284 
38. Ferrero, P., Santi, M. R., Conti-Tronconi, B., Costa, E., and Guidotti, A. 
(1986) Proc Natl Acad Sci U S A 83(3), 827-831 
39. Ferrarese, C., Cogliati, T., Tortorella, R., Zucca, C., Bogliun, G., Beghi, E., 
Passoni, D., Zoia, C., Begni, B., Airoldi, L., Alho, H., and Frattola, L. (1998) 
Epilepsy Res 29(2), 129-134 
40. Ferrarese, C., Appollonio, I., Frigo, M., Meregalli, S., Piolti, R., Tamma, F., 
and Frattola, L. (1990) Neurology 40(4), 632-635 
41. Ferrero, P., Benna, P., Costa, P., Tarenzi, L., Baggio, G., Bergamasco, B., 
and Bergamini, L. (1988) J Neurol Sci 87(2-3), 327-349 
42. Thoeringer, C. K., Binder, E. B., Salyakina, D., Erhardt, A., Ising, M., 
Unschuld, P. G., Kern, N., Lucae, S., Brueckl, T. M., Mueller, M. B., Fuchs, 
B., Puetz, B., Lieb, R., Uhr, M., Holsboer, F., Mueller-Myhsok, B., and Keck, 
M. E. (2007) J Psychiatr Res 41(7), 579-584 
43. Katsura, M., Ohkuma, S., Xu, J., Hibino, Y., Tsujimura, A., and Kuriyama, 
K. (1998) Brain Res Mol Brain Res 55(2), 345-349 
44. Katsura, M., Ohkuma, S., Tsujimura, A., and Kuriyama, K. (1995) J 
Pharmacol Exp Ther 273(3), 1529-1533 
45. Siiskonen, H., Oikari, S., Korhonen, V. P., Pitkanen, A., Voikar, V., 
Kettunen, M., Hakumaki, J., Wahlfors, T., Pussinen, R., Penttonen, M., 
References 
 22 
Kiehne, K., Kaasinen, S. K., Alhonen, L., Janne, J., and Herzig, K. H. 
(2007) Mol Cell Neurosci 34(2), 199-208 
46. Yanagibashi, K., Ohno, Y., Kawamura, M., and Hall, P. F. (1988) 
Endocrinology 123(4), 2075-2082 
47. Besman, M. J., Yanagibashi, K., Lee, T. D., Kawamura, M., Hall, P. F., and 
Shively, J. E. (1989) Proc Natl Acad Sci U S A 86(13), 4897-4901 
48. Bovolin, P., Schlichting, J., Miyata, M., Ferrarese, C., Guidotti, A., and Alho, 
H. (1990) Regul Pept 29(2-3), 267-281 
49. Garnier, M., Boujrad, N., Oke, B. O., Brown, A. S., Riond, J., Ferrara, P., 
Shoyab, M., Suarez-Quian, C. A., and Papadopoulos, V. (1993) 
Endocrinology 132(1), 444-458 
50. Agerberth, B., Boman, A., Andersson, M., Jornvall, H., Mutt, V., and 
Boman, H. G. (1993) Eur J Biochem 216(2), 623-629 
51. Solstad, T., Fismen, L., Garberg, H., and Fladmark, K. E. (2008) Exp Cell 
Res  
52. Taupin, V., Herbelin, A., Descamps-Latscha, B., and Zavala, F. (1991) 
Lymphokine Cytokine Res 10(1-2), 7-13 
53. Taupin, V., Gogusev, J., Descamps-Latscha, B., and Zavala, F. (1993) Mol 
Pharmacol 43(1), 64-69 
54. Mandrup, S., Jepsen, R., Skott, H., Rosendal, J., Hojrup, P., Kristiansen, K., 
and Knudsen, J. (1993) Biochemical Journal 290, 369-374 
55. Knudsen, J., Faergeman, N. J., Skott, H., Hummel, R., Borsting, C., Rose, 
T. M., Andersen, J. S., Hojrup, P., Roepstorff, P., and Kristiansen, K. (1994) 
Biochem J 302 (Pt 2), 479-485 
56. Huang, H., Atshaves, B. P., Frolov, A., Kier, A. B., and Schroeder, F. (2005) 
Biochemistry 44(30), 10282-10297 
57. Oikari, S., Ahtialansaari, T., Heinonen, M. V., Mauriala, T., Auriola, S., 
Kiehne, K., Folsch, U. R., Janne, J., Alhonen, L., and Herzig, K. H. (2007) 
Pflugers Arch  
58. Rasmussen, J. T., Rosendal, J., and Knudsen, J. (1993) Biochemical 
Journal 292, 907-913 
59. Faergeman, N. J., and Knudsen, J. (1997) Biochemical Journal 323, 1-12 
60. Chao, H., Martin, G. G., Russell, W. K., Waghela, S. D., Russell, D. H., 
Schroeder, F., and Kier, A. B. (2002) Biochemistry 41(33), 10540-10553 
61. Abo-Hashema, K. A. H., Cake, M. H., Lukas, M. A., and Knudsen, J. (2001) 
International Journal of Biochemistry & Cell Biology 33(8), 807-815 
62. Fyrst, H., Knudsen, J., Schott, M. A., Lubin, B. H., and Kuypers, F. A. 
(1995) Biochemical Journal 306, 793-799 
63. Kerkhoff, C., Beuck, M., ThreigeRasmussen, J., Spener, F., Knudsen, J., 
and Schmitz, G. (1997) Biochimica et Biophysica Acta-Lipids and Lipid 
Metabolism 1346(2), 163-172 
64. Bhuiyan, J., Pritchard, P. H., Pande, S. V., and Seccombe, D. W. (1995) 
Metabolism-Clinical and Experimental 44(9), 1185-1189 
65. Helledie, T., Grontved, L., Jensen, S. S., Kiilerich, P., Rietveld, L., 
Albrektsen, T., Boysen, M. S., Nohr, J., Larsen, L. K., Fleckner, J., 
Stunnenberg, H. G., Kristiansen, K., and Mandrup, S. (2002) Journal of 
Biological Chemistry 277(30), 26821-26830 
66. Swinnen, J. V., Alen, P., Heyns, W., and Verhoeven, G. (1998) Journal of 
Biological Chemistry 273(32), 19938-19944 
67. Sandberg, M. B., Bloksgaard, M., Duran-Sandoval, D., Duval, C., Staels, B., 
and Mandrup, S. (2005) J Biol Chem 280(7), 5258-5266 
References 
 23 
68. Neess, D., Kiilerich, P., Sandberg, M. B., Helledie, T., Nielsen, R., and 
Mandrup, S. (2006) Mol Cell Biochem, 1-9 
69. Swinnen, J. V., Esquenet, M., Heyns, W., Rombauts, W., and Verhoeven, 
G. (1994) Mol Cell Endocrinol 104(2), 153-162 
70. Swinnen, J. V., Vercaeren, I., Esquenet, M., Heyns, W., and Verhoeven, G. 
(1996) Mol Cell Endocrinol 118(1-2), 65-70 
71. Hansen, H. O., Andreasen, P. H., Mandrup, S., Kristiansen, K., and 
Knudsen, J. (1991) Biochem J 277 (Pt 2), 341-344 
72. Petrescu, A. D., Payne, H. R., Boedecker, A., Chao, H., Hertz, R., Bar-
Tana, J., Schroeder, F., and Kier, A. B. (2003) Journal of Biological 
Chemistry 278(51), 51813-51824 
73. Li, Q., Yamamoto, N., Morisawa, S., and Inoue, A. (1993) J Cell Biochem 
51(4), 458-464 
74. Jump, D. B., Botolin, D., Wang, Y., Xu, J., Christian, B., and Demeure, O. 
(2005) J Nutr 135(11), 2503-2506 
75. Swinnen, J. V., Esquenet, M., Rosseels, J., Claessens, F., Rombauts, W., 
Heyns, W., and Verhoeven, G. (1996) Dna and Cell Biology 15(3), 197-208 
76. Fisher, E., Nitz, I., Gieger, C., Grallert, H., Gohlke, H., Lindner, I., Dahm, S., 
Boeing, H., Burwinkel, B., Rathmann, W., Wichmann, H. E., Schrezenmeir, 
J., Illig, T., and Doring, F. (2007) Mol Nutr Food Res 51(2), 178-184 
77. De Souza, A. T., Dai, X., Spencer, A. G., Reppen, T., Menzie, A., Roesch, 
P. L., He, Y., Caguyong, M. J., Bloomer, S., Herweijer, H., Wolff, J. A., 
Hagstrom, J. E., Lewis, D. L., Linsley, P. S., and Ulrich, R. G. (2006) 
Nucleic Acids Res 34(16), 4486-4494 
78. Weisschuh, N., Alavi, M. V., Bonin, M., and Wissinger, B. (2007) Exp Eye 
Res 85(4), 450-461 
79. Shoda, J., Inada, Y., Tsuji, A., Kusama, H., Ueda, T., Ikegami, T., Suzuki, 
H., Sugiyama, Y., Cohen, D. E., and Tanaka, N. (2004) J Lipid Res 45(10), 
1813-1825 
80. Evans, J. R., Kelly, D. L., Morris, K. J., Arvide, E. M., and Harris, A. (2008) 
Biochim Biophys Acta 1779(5), 341-346 
81. Ohgami, R. S., Campagna, D. R., Antiochos, B., Wood, E. B., Sharp, J. J., 
Barker, J. E., and Fleming, M. D. (2005) Blood 106(10), 3625-3631 
82. Faergeman, N. J., Feddersen, S., Christiansen, J. K., Larsen, M. K., 
Schneiter, R., Ungermann, C., Mutenda, K., Roepstorff, P., and Knudsen, J. 
(2004) Biochem J 380(Pt 3), 907-918 
83. Bunger, M., Hooiveld, G. J., Kersten, S., and Muller, M. (2007) Biochim 
Biophys Acta 1771(8), 1046-1064 
84. Dolt, K. S., Karar, J., Mishra, M. K., Salim, J., Kumar, R., Grover, S. K., and 
Qadar Pasha, M. A. (2007) Biochem Biophys Res Commun 354(1), 148-
153 
85. Feddersen, S., Neergaard, T. B., Knudsen, J., and Faergeman, N. J. (2007) 
Biochem J  
86. Boujrad, N., Hudson, J. R., Jr., and Papadopoulos, V. (1993) Proc Natl 
Acad Sci U S A 90(12), 5728-5731 
87. Goldstein, J. L., and Brown, M. S. (1990) Nature 343(6257), 425-430 
88. Papadopoulos, V., and Brown, A. S. (1995) J Steroid Biochem Mol Biol 
53(1-6), 103-110 
89. Simpson, E. R., and Waterman, M. R. (1983) Can J Biochem Cell Biol 
61(7), 692-707 
90. Kato, M., and Wickner, W. (2001) Embo J 20(15), 4035-4040 
References 
 24 
91. Simons, K., and Ikonen, E. (1997) Nature 387(6633), 569-572 
92. Bretscher, M. S., and Munro, S. (1993) Science 261(5126), 1280-1281 
93. Maston, G. A., Evans, S. K., and Green, M. R. (2006) Annu Rev Genomics 
Hum Genet 7, 29-59 
94. Sladek, F. M., Zhong, W. M., Lai, E., and Darnell, J. E., Jr. (1990) Genes 
Dev 4(12B), 2353-2365 
95. Olsen, L., Bressendorff, S., Troelsen, J. T., and Olsen, J. (2005) Am J 
Physiol Gastrointest Liver Physiol 289(2), G220-226 
96. Murayama, A., Kim, M. S., Yanagisawa, J., Takeyama, K., and Kato, S. 
(2004) Embo J 23(7), 1598-1608 
97. Solstad, T., Fismen, L., Garberg, H., and Fladmark, K. E. (2008) Exp Cell 
Res 314(10), 2141-2149 
98. Elholm, M., Dam, I., Jorgensen, C., Krogsdam, A. M., Holst, D., 
Kratchmarova, I., Gottlicher, M., Gustafsson, J. A., Berge, R., Flatmark, T., 
Knudsen, J., Mandrup, S., and Kristiansen, K. (2001) J Biol Chem 276(24), 
21410-21416 
99. Hertz, R., Magenheim, J., Berman, I., and Bar-Tana, J. (1998) Nature 
392(6675), 512-516 
100. Hertz, R., Sheena, V., Kalderon, B., Berman, I., and Bar-Tana, J. (2001) 
Biochem Pharmacol 61(9), 1057-1062 
101. Hertz, R., Bishara-Shieban, J., and Bar-Tana, J. (1995) J Biol Chem 
270(22), 13470-13475 
102. McChesney, P. A., Aiyar, S. E., Lee, O. J., Zaika, A., Moskaluk, C., Li, R., 
and El-Rifai, W. (2006) Cancer Res 66(3), 1346-1353 
103. Cherasse, Y., Maurin, A. C., Chaveroux, C., Jousse, C., Carraro, V., Parry, 
L., Deval, C., Chambon, C., Fafournoux, P., and Bruhat, A. (2007) Nucleic 
Acids Res 35(17), 5954-5965 
104. Sun, S., Tang, Y., Lou, X., Zhu, L., Yang, K., Zhang, B., Shi, H., and Wang, 
C. (2007) J Cell Biol 178(2), 231-244 
 
 
Submitted Manuscripts  
 25 
Submitted Manuscripts  
 
Chapter I 
 
ACBP knockdown leads to down-regulation of genes encoding rate-limiting 
enzymes in cholesterol and fatty acid metabolism 
 
 
 
Chapter II 
 
Regulation of the rate-limiting cholesterogenic enzymes HMG-CoA synthase and 
HMG-CoA reductase by human ACBP 
 1 
ACBP knockdown leads to down-regulation of genes encoding rate-limiting 
enzymes in cholesterol and fatty acid metabolism  
 
 
Christina Vock1, Katrin Biedasek3, Inka Boomgaarden1, Anja Heins2, Inke Nitz1, 
Frank Döring1 
 
1Molecular Nutrition, Christian-Albrechts-University of Kiel, Heinrich-Hecht-Platz 10, 
D-24118 Kiel, Germany 
2Food Technology, Christian-Albrechts-University of Kiel, Heinrich-Hecht-Platz 10, D-
24118 Kiel, Germany 
3Department of Endocrinology, Diabetes and Nutrition, Charité-University-Medicine, 
Campus Benjamin Franklin, Free University of Berlin, Germany 
 
 
Running head: ACBP knockdown and gene expression 
 
 
 
Corresponding author  
Tel. +49 431 880 5657, fax +49 431 880 5658 
E-mail address: sek@molnut.uni-kiel.de 
 
 2 
Abstract 
The human Acyl-CoA binding protein (ACBP) is a structural and functional highly 
conserved protein. As an intracellular pool former and carrier of acyl-CoAs, ACBP 
influences the overall lipid metabolism. Its nuclear abundance and physical 
interaction with hepatocyte nuclear factor 4α suggested a gene regulatory function of 
ACBP. In order to identify ACBP target genes we performed genome-wide transcript 
profiling under siRNA-mediated ACBP knockdown in human liver HepG2 cells. 
Based on a single sided permutation T-test (p<0.05) we identified 256 down-
regulated and 198 up-regulated transcripts with a minimal fold change of 1.32 (log 
0.5). TaqMan-based qRT-PCR of 10 selected genes confirmed high accuracy of the 
array data. Gene annotation enrichment analysis revealed ACBP-mediated down-
regulation of 18 genes encoding key enzymes in glycerolipid (i.e. mitochondrial 
glycerol-3-phosphate acyltransferase), cholesterol (i.e. HMG-CoA synthase and 
HMG-CoA reductase) and fatty acid (i.e. fatty acid synthase) metabolism. Integration 
of these genes in common pathways suggested a decrease of lipid biosynthesis 
under ACBP knockdown. Accordingly, saturated (16:0) and monosaturated (16:1, 
18:1) fatty acids were significantly reduced to 75% in ACBP-depleted cells. Taken 
together, we obtained evidence that ACBP functions in lipid metabolism at the level 
of gene expression. This effect seems to be translated into certain metabolites. The 
identified 454 ACBP regulated genes present a first reference for further studies to 
define the ACBP regulon in mammalian cells.  
 
 
Keywords: RNAi, ACBP, HepG2 cells, fatty acids, cholesterol metabolism 
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Introduction 
 
The human Acyl-CoA binding protein (ACBP) is a highly conserved protein, which 
can be found in nearly all eukaryotes. It is a typical housekeeping gene, although it’s 
expression varies between different cells and tissues (33). ACBP possesses a 
number of important physiological and biochemical functions, such as inhibition of 
diazepam binding to benzodiazepine binding site of gamma-aminobutyric acid-ergic 
(GABA)-receptor (21, 22), regulation of glucose-induced insulin secretion from 
pancreatic beta-cells (3, 6), release of cholecystokinin (CCK) in intestine (26), 
stimulation of steroidogenesis through peripheral-type benzodiazepine receptor 
(PBR) (2, 4, 42) and modulation of cell proliferation (18). ACBP seems also to be part 
of the calcium-dependent proteolytic system through the activation of calpains (37). 
In this respect ACBP seems to be involved in pro-apoptotic processes and cell death 
(52).  
ACBPs participation in acyl-CoA metabolism is well established and supported by its 
ability to bind and sequester long chain acyl-CoAs (LCFACoA) with high affinity. This 
suggests that ACBP functions as intracellular carrier and pool former of LCFACoA. 
Thereby, ACBP protects membranes and transport functions as well as enzymes 
against LCFACoAs detergenic and inhibitory effects (30, 34, 47, 55). Furthermore, 
ACBP mediates intermembrane transport of acyl-CoAs by displacing them from 
membranes and donating them to utilizing enzymes, i.e. ß-oxidation in mitochondria, 
microsomal glycerolipid synthesis and cholesteryl ester acylation (7, 44, 45). Yeast 
studies applying Acb1p (the yeast homologue of ACBP) overexpression or knockout, 
substantiate the proteins function in overall lipid metabolism. Especially knockout of 
ACBP evoked profound changes in membrane structure, assembly and organization 
(17). Loss of ACBP in mice causes defective cutaneous fatty acid metabolism (31).  
 
ACBP is localized throughout the cytosol and at special cell organelles as Golgi 
apparatus or endoplasmic reticulum (23), in nucleus and in the perinuclear area (43). 
Except for a distinct nuclear localization during adipocyte differentiation (24), a 
functional relevance for ACBPs nuclear abundance is not known. A direct impact of 
ACBP on gene regulation was shown by Petrescu et al. (2003), which reported 
physical and functional interaction with the hepatocyte nuclear factor (HNF)-4α (43). 
Expression profiling in Acb1p yeast knockout strain revealed transcriptional changes 
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which were however not complementable by an Acp1p mutant unable to bind acyl-
CoA esters. This supports finally the idea of ligand-mediated impact of ACBP on 
gene expression (16).  
Here, a genome-wide expression profiling approach was applied in HepG2 
cells to identify human ACBP target genes and their functional allocation. Therefore 
we performed siRNA mediated knockdown of ACBP and the resulting changes in 
gene expression were assessed with Affymetrix microarray technology. Our study 
shows, that ACBP-depletion in HepG2 cells reduces the transcript levels of central 
rate-limiting enzymes of cholesterol, fatty acid as well as glycerolipid synthesis. 
Accordingly, the fatty acid content of ACBP-depleted cells was also reduced  
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Material & Methods 
 
Cell culture  
The human hepatocellular carcinoma cell line HepG2 was cultured in RPMI-Medium 
+ 1% Glutamax (Invitrogen, Carlsbad, USA) containing 10% fetal calf serum in a 5% 
CO2/95% air atmosphere at 37°C. Media was replaced every two days and cells were 
passaged at subconfluency with 0.25% Trypsin in PBS to maintain exponential 
growth.  
 
siRNA design 
Two ACBP specific stability enhanced twenty-one-nucleotide short interfering RNAs 
(siRNAs), were purchased from Dharmacon Research (Lafayette, USA). siRNA1 (5’- 
GAAAAAATACGGGATATGA -3’), located in exon 4 at 246-264 bp relative to ATG 
start codon 1A, was designed according to Reynolds design criteria (46) and in 
consideration of RNA secondary structure. To assess secondary structure of ACBP 
mRNA (NM_001079862) we used the Mfold web server (57). siRNA2 (5’- 
GGAAGATGCCATGAAAGCT -3’) located in exon 4 at 201-219 bp relative to ATG 
start codon was according to Faergeman et al. (15). Sequence information about 
ACBP was taken from GenBank (NCBI, http://www.ncbi.nlm.nih.gov). To avoid off-
targeting effects of the designed siRNAs, sequence comparisons of the ACBP 
protein family and ACBP domain containing proteins were done using web based 
alignment tools at NCBI and EBI (http://www.ebi.ac.uk). Control siRNAs targeted to 
Lamin A/C, Cyclophilin B and a stabilized scrambled siRNA were also obtained from 
Dharmacon Research Inc. 
 
Transient Transfection  
For transfection experiments 1.1x105 cells were seeded in 24-well plates (Sarstedt, 
Newton, USA). Cells were transfected at 30-40% confluency in a final siRNA 
concentration of 100nmol/L with Dharmafect4 transfection reagent (Dharmacon 
Research, Lafayette, USA) according to the manufacturer’s instructions. 24 h post-
transfection medium was changed. Cells treated with transfection reagent were used 
as negative control (mock control).  
Transfection efficiency was initially monitored with fluorescein-labeled siRNA 
(Qiagen, Hilden, Germany) by microscopy.  
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Real-time RT-PCR analysis  
Real-time reverse transcriptase PCR (RT-PCR) was carried out on total RNA from 
HepG2 cells transfected with ACBP specific or scrambled siRNA after 24 h, 36 h and 
48 h on an ABI PRISM 7000 Sequence Detection System instrument (PE Applied 
Biosystems, Foster City, CA). For RNA isolation RNeasy Kit (Qiagen, Hilden, 
Germany), for cDNA preparation iScript cDNA synthesis kit (BioRad Laboratories, 
Hercules, USA) were used. cDNA was diluted 1:5 with RNase-free H2O before PCR 
analysis. Differential regulated target genes identified by the expression profiling 
approach were verified accordingly. Each real-time RT-PCR reaction was done in 
triplicate according to manufacturer’s instructions. Gene expression assays [ACBP 
(Hs01554584_m1), 3-hydroxy-3-methylglutaryl-CoA synthase (Hs_00266810_m1), 3-
hydroxy-3-methylglutaryl-CoA reductase (Hs_00168352_m1), isopentenyl-
diphosphate delta isomerase 1 (Hs_01057440_m1), lanosterol synthase 
(Hs_01057440_m1), acyl-CoA:cholesterol acyltransferase 2 (Hs_00186048_m1), 
fatty acid synthase (Hs_00188012_m1), mitochondrial glycerol-3-phosphate 
acyltransferase (Hs_00326039_m1), peroxisomal trans 2-enoyl CoA reductase 
(Hs_00218365_m1), early growth response 1 (Hs_00152928_m), 3-hydrox-3-
methylglutaryl-CoA lyase (Hs_00609306_m1)] were obtained from ABI. Quantities of 
target mRNA were determined via standard curves using hypoxanthine 
phosphoribosyl-transferase 1 (HPRT1) as endogenous control. Two negative 
controls (-reverse transcriptase/-RNA template) were included to detect possible 
contaminations.  
 
Cytotoxicity and apoptosis assays 
Cytotoxicity was determined 72 h after transfection of HepG2 cells using CellTiter-
Glo® Luminescent Cell Viability Assay (Promega, Mannheim, Germany) according to 
manufacturer’s instructions with regard of modified lysis time of 30 min. 
Luminescence was measured in a GloMax™ microplate luminometer (Promega, 
Mannheim, Germany) as a signal proportional to the amount of ATP present in 
metabolically active cells.  
Caspase 3 and/ or caspase 7 activity was determined 72 h post-transfection using 
the Caspase-Glo™ 3/7 Assay (Promega, Mannheim, Germany) according to the 
manufacturer's instructions with prolonged lysis of 30 min. Camptothecin (Sigma 
Aldrich, Saint Louis, USA) was used as a positive control for apoptosis induction. 16 
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h before caspase 3/7 measurement cells were incubated with 5µmol/L Camptothecin. 
All experiments were performed at least in triplicate.  
Gas chromatography 
For fatty acid analysis, 4x105 HepG2 cells were plated on 6-well dishes. Transfection 
of ACBP specific and scrambled control siRNA was performed as described above. 
Accordingly, 72 h post-transfection cells were trypsinized, resuspended in PBS and 
stored at -80°C. For GC-analysis cells were extracted in dichloromethane:methanol 
(2:1). Methyl margaric acid (C17:0; 250 µg) was added as internal standard. After 
incubation for 15 min at 37°C, lipid phase was extracted using a CaCl2 (0.04%)-
solution in HPLC H2O and dichloromethane/methanol. For preparation of fatty acid 
methyl esters (FAME) solvents were evaporated under nitrogen, remixed with 1.5 ml 
methanolic NaOH (0.5 M), and incubated at 105°C for 30 min. After adding 2 ml 
boron trifluoride, samples were incubated another 35 min at 105°C. 5 ml saturated 
NaCl-solution and 2 x 1 ml isooctane were added. The upper phase was used for gas 
chromatography analysis, performed on Hewlett-Peckard 6890 gas chromatograph 
equipped with a J&W 122-2362 DB-23 capillary column (Agilent, Palo Alto, USA) with 
hydrogen carrier flow rate at 40 ml/min, and air at 450 ml/min. Injection split was 
1:20. The following temperature program was used: first temperature was set at 
80°C, 25°C/min to 180°C, hold for 2 min, 2°C/min to 182°C, hold for 16 min, 6°C/min 
to 197°C, hold for 10 min, 40°C/min to 240°C, hold for 2 min, at least 250°C for 10 
min. FAMEs were detected by a flame ionization detector. Sample peaks were 
compared with retention times of known standards for specific fatty acid identification. 
 
Microarray experiment  
Microarray experiments were performed on the human Genome U133 Plus 2.0 
Genechip array (Affymetrix, Santa Clara, USA). For the experiments 4x105 HepG2 
cells were seeded in 6-well plates and transfected after 24 h with 100 nmol/L ACBP-
specific siRNA1 or scrambled siRNA as control for 72 h. Total RNA was prepared 
with RNeasy Kit (Qiagen, Hilden, Germany). RNA amount and integrity was 
assessed spectrophotometrically (BioPhotometer, Eppendorf, Hamburg, Germany) 
and by using the Bioanalyzer (Agilent, Palo Alto, USA). Experiments were done in 
triplicate and each approach consisted 3 pooled wells. 
Processing and statistical analysis was done by the KFB-Center of Excellence for 
Fluorescent Bioanalysis (University of Regensburg, Germany) based on Affymetrix 
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protocols (Affymetrix, Santa Clara, USA). The samples were hybridized to the human 
genome array which contains ~38,500 full-length human genes and EST clusters. 
Digitized chip image data were processed using Affymetrix GeneChip Analysis Suite 
software version 5.0 (MAS5.0). Comparison of expression profiles from the 
scrambled siRNA control (set as baseline) and the ACBP specific siRNA1 transfected 
sample (designated as the experiment) was done with Genomatix ChipInspector 
software (Munich, Germany), which includes a single sided permutation T-test. For 
determination of differentially regulated genes the fold change was set 1.32 and false 
discovery rate (FDR) rests with 1%. Beside that, only significant detected transcripts 
after MAS5.0, as a single-rank call algorithm, were taken for further analysis (32).  
 
Computational analysis 
Gene Ontology (GO) functional classification was performed using Database for 
Annotation, Visualization and Integrated Discovery (DAVID) 
(www.david.abcc.ncifcrf.gov/home.jsp) (9). Classification according biological 
processes and molecular function was performed on GO term level 2. Statistical 
significant GO terms with a p-value lower than 0.05, based on Benjamini-Hochberg 
correction for multiple testing, were presented. We utilized the text-mining system 
Genomatix BiblioSphere Pathway Edition (BSPE) (www.genomatix.de) to identify the 
putative functional connection between the 454 regulated target genes. BSPE is 
based on co-citation of gene names and synonyms (48). The lowest co-citation filter 
(GFG level G0) based on abstract level was applied. Subsequent sub-analysis was 
applied by filtering differential regulated genes according to the GO-term of cellular 
lipid metabolic process. Promoter sequences of selected target genes were adopted 
from Genomatix Gene2Promoter. Promoter length was adjusted to 600 bp, 500 bp 
upstream and 100 bp downstream of transcriptional start site (TSS). Promoter 
sequences were subjected to in silico promoter analysis using Genomatix 
MatInspector to search for common transcription factor binding sites (TFBS). TFBS 
were represented by position weight matrices from the Genomatix Family library 
(Version 7.0) (5, 29).  
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Statistical analysis  
Statistical analysis was performed with GraphPad Prism4 (Graphpad software, Inc., 
San Diego, USA) using 2-tailed Student´s paired t-test. All values were expressed as 
mean ± SD. Significant differences were considered for P values less than 0.05. 
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Results  
 
siRNA-mediated knockdown of ACBP expression in HepG2 cells  
For ACBP knockdown we have designed two specific siRNA sequences and 
analyzed their silencing effect in HepG2 cells. A non-silencing scrambled siRNA 
served as a negative control. Based on a fluorescence-labeled siRNA, transfection 
efficiency was between 50-70% (data not shown). Using 100 nmol/L ACBP-siRNA1 
or -siRNA2, a reduction of ACBP-mRNA levels to 63% and 73% was observed 24 h 
after transfection, respectively (Fig. 1A). 36 h post-transfection, a reduction of ACBP-
mRNA to 39% (siRNA1) and 48% (siRNA2) could be obtained. No further silencing 
effect was achieved by increasing transfection time to 48 h where ACBP-mRNA 
levels were decreased to 48% (siRNA1) or 54% (siRNA2). At protein level, both 
ACBP-siRNAs caused an approximately 80% reduction of ACBP 72 h post- 
transfection in HepG2 cells (Fig. 1B). Thus, we were able to establish siRNA-
mediated knockdown of ACBP at mRNA and protein level in HepG2 cells.  
 
Cytotoxic or pro-apoptotic events are not evoked by ACBP knockdown 
Since ACBP is described as a cell death promoting protein (53) we determined 
whether ACBP knockdown causes cytotoxicity and/or apoptosis in HepG2 cells. For 
this purpose, 72 h after transfection of ACBP-siRNAs or control siRNAs, cell viability 
and apoptosis were determined using ATP and caspase 3/7 measurements. As 
shown in Fig. 2A, transfection of scrambled siRNA, lamin A/C-siRNA, or cyclophilin 
B-siRNA is not accompanied by cytotoxic effects. Importantly, the cell viability is not 
pertubated by ACBP knockdown. For apoptotic measurements, the well known pro-
apoptotic agent camptothecin serves as a positive control. As shown in Fig. 2B, 
camptothecin raised caspase 3/7 activity to about 2042% compared to mock cells. 
ACBP-siRNA1 did not increase caspase 3/7 activity in comparison to scrambled- or 
cyclophilin B-siRNA. In contrast, lamin A/C-siRNA and ACBP-siRNA2 increase the 
caspase 3/7 activity significantly. Therefore, we used the non-cytotoxic and non-
apoptotic ACBP-siRNA1 for ongoing experiments. 
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Transcript profiling under ACBP knockdown showed 454 differential regulated 
genes in HepG2 cells 
A profound depletion of ACBP protein to 20% compared to scrambled control siRNA 
was observed 72 h after siRNA transfection of HepG2 cells. This experimental set-up 
was used in order to identify putative ACBP-regulated genes. We performed 
microarray analyses applying human Genome U133 Plus 2.0 Genechip arrays 
(Affymetrix) in three independent experiments and compared the mRNA profile of 
control cells (scrambled siRNA) with ACBP-depleted cells. Based on a single sided 
permutation T-test and “present” designated probe sets with a minimal fold change of 
1.32 (log 0.5) we identified 454 transcripts which were consistently regulated under 
ACBP-depletion. 256 transcripts were down- and 198 were up-regulated. As a 
mandatory control of our whole set-up, we found a down-regulation of the ACBP-
mRNA by a factor of 2.35±0.19 (mean±SD). As a further control, 10 transcripts were 
selected for verification by TaqMan-based qRT-PCR. As shown in Table 2, we 
verified all selected genes. The consistency between array and qRT-PCR data is 
mentionable. For example, array data revealed a down-regulation of the PECR-gene 
with a fold change of -1.53±0.01 (mean±SD) whereas qRT-PCR shows a factor of  
-1.49±0.09. Taken together, we identified 454 ACBP-regulated genes with high 
accuracy and assurance by using an RNAi-approach and whole genome expression 
profiling in HepG2 cells.  
 
Gene annotation enrichment analysis revealed that ACBP-regulated genes are 
involved in fatty acid, glycerolipid and cholesterol metabolism 
To allocate the corresponding genes of regulated transcripts with regard to biological 
processes and molecular function the functional annotation tool DAVID was applied. 
We used Gene Ontology (GO) classification of level 2 which maintains good term 
coverage and provides meaningful term specificity (9). Table 1 shows the number of 
ACBP-regulated genes which are significantly overrepresented in certain GO-terms. 
For example, 169 genes allocate to the term regulation of biological processes, 156 
genes assign to regulation of cellular processes and 102 allocate to cellular 
component organization and biogenesis. According to molecular function half of the 
ACBP-regulated genes allocate to protein binding. As a second approach to allocate 
identified genes we used the text-mining system BibliospherePathwayEdition (BSPE) 
which allows a more comprehensive sub-analysis. Since ACBP has a designated 
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function in fatty acid and steroid metabolism, we subsequently filtered 223 ACBP-
regulated genes according to the GO-classification cellular metabolic process and 
cellular lipid metabolic process. Based on this, we identified 16 down-regulated and 4 
up-regulated genes (Tab. 2) allocated to cellular lipid metabolic process. Independent 
from GO-based gene selection we identified the 3-hydroxy-3-methylglutaryl-
Coenzyme A lyase (HMGCL; +1.33) and the early growth response 1 gene (EGR1; -
1.67) as regulated by ACBP. Thus, we subjected 22 ACBP regulated to further sub-
analysis. A consistent down-regulation of four genes involved in cholesterol 
biosynthesis was observed: 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 
(HMGCS1; -1.60), 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (HMGCR; -
1.36), isopentenyl-diphosphate delta isomerase 1 (IDI1; -1.32) and lanosterol 
synthase (LSS; -1.37). Acyl-CoA:cholesterol acyltransferase 2 (ACAT2; +1.35) was 
up-regulated. Eight differential expressed genes were involved in fatty acid metabolic 
processes, including acyl-CoA oxidase (ACOX1; -1.35), CD74 molecule (CD74; 
+1.39); cytochrome P450, family 4, subfamily F, polypeptide 3 (CYP4F3; +1.32); 
ELOVL family member 6 (ELOVL6; -1.34); liver fatty acid binding protein (L-FABP 1; 
-1.39), fatty acid synthase (FASN; -1.40), peroxisomal trans 2-enoyl CoA reductase 
(PECR; -1.53) and protein kinase, AMP-activated, beta 2 non-catalytic subunit 
(PRKAB2; -1.49). Three regulated genes encoded enzymes involved in membrane 
lipid metabolic processes: mitochondrial glycerol-3-phosphate acyltransferase 
(GPAM; -1.45); inositol (myo)-1(or 4)-monophosphatase 1 (IMPA1; -1.49) and ST3 
beta-galactoside alpha-2,3-sialyltransferase 6 (ST3GAL6; -1.39).  
 
ACBP knockdown reduces the fatty acid content in HepG2 cells 
ACBP-regulated genes involved in lipid metabolism (Tab. 2, n=22) were allocated 
into common metabolic pathways based on literature and database searches. As 
shown in Fig. 3, 10 regulated genes encode key enzymes which could be integrated 
into fatty acid, glycerolipid and cholesterol metabolism. As described, the regulation 
of these genes was verified by qRT-PCR (Tab. 2). A close inspection of the depicted 
metabolism suggested a down-regulation of lipid biosynthetic pathways. 
Consequently, we determined fatty acid content in HepG2 cells after ACBP 
knockdown. As shown in Fig. 4, saturated (16:0) and monosaturated (16:1, 18:1) 
fatty acid were significantly reduced to nearly 75% in ACBP-depleted cells. Thus, the 
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ACBP-siRNA mediated down-regulation of the lipid metabolism at mRNA-level 
seems to be translated into the relevant metabolites.  
 
In silico promoter analysis of ACBP target genes 
We performed in silico promoter analysis to identify common regulatory motifs in the 
20 ACBP regulated genes allocating the GO-term cellular lipid metabolic process 
(Tab. 2). Promoter sequences were extracted and analyzed according common 
transcription factor binding sites (TFBS). Comparative analysis resulted in the 
significant identification of TFs belonging to EGR/nerve growth factor induced protein 
C & related factor (EGRF) (p=4.33E-6), zinc factor binding protein factors (ZFBP) 
(p=8.75E-4) and GC-Box factors SP1/GC (SP1) (p=1.2 E-3) family. Based on the 
observed transcriptional repression of EGR1 we concentrated on EGR-family. Sub- 
analysis allocated putative binding sites for EGR1 in 16 of total 20 differential 
expressed genes: ACOX1, CMAS, ELOVL6, FASN, GPAM, HMGCR, HMGCS1, 
IDI1, IMPA1, LSS, PECR, PNPLA3, PRKAB2, RDH11, SBF2, ST3GAL6.  
Four identified target genes seem not be regulated by EGR1, possess however 
putative TFBS for other EGR-family members. CD74 might be regulated by Wilms 
tumor 1 (WT1) and nerve growth factor-induced protein C (NGFIC). WT 1 and EGR2 
seem to bind to CYP4F3 promoter, whereas EGR2 possesses a target site in 
FABP1-promoter and collagen krox protein (CKROX) in ACAT2-promoter.  
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Discussion  
The ubiquitous expressed multifunctional protein ACBP is a well known intracellular 
transporter of acyl-CoAs thereby determining profoundly their intracellular fate. 
Through binding and directing acyl-CoAs towards nucleus and nuclear factors ACBP 
may influence gene expression (25). Supportively, ACBP is located in the nucleus 
(12) and interacts with HNF-4α (43). Here we aimed to unravel the impact of human 
ACBP in gene expression by applying RNAi-mediated silencing of ACBP in HepG2 
cells in combination with microarray gene chip technology. We achieved a down-
regulation of the ACBP protein of about 80%. Similar reductions were also reported 
in other siRNA-mediated knockdown studies (13, 51, 56). Our microarray approach 
revealed high accuracy because the measured transcript levels by microarray were 
very consistent to qRT-PCR verification data. In comparison to complex tissues 
available form ACBP overexpressing (27, 41) and knockout mice (31), our approach 
employed a homogenous cell population cultured under highly standardized 
conditions. Therefore, the identified 454 ACBP regulated transcripts in liver HepG2 
cells is an appropriate collection to unravel the cellular function of ACBP in gene 
expression.  
 
The broad abundance of the multifunctional ACBP in the eukaryotic kingdom could 
be a hint for its essential function. Indeed, target disruption of ACBP in the parasite 
Trypanosoma brucei leads to lethality (38). In ACBP-depleted yeast a retarded cell 
growth was described (49). A mutation within the ACBP locus in mice resulted in 
sparse hair, male infertility, failure to thrive, hydrocephaly and anemia (40). 
Furthermore, Faergeman et al. (15) showed growth arrest, cell detachment and 
apoptosis-induction in ACBP-depleted HepG2, HeLa and Chang cells. In contrast but 
in accordance to our study in HepG2 cells, ACBP knockdown in murine 3T3-L1 
fibroblasts (35) and HeLa cells (52) did not point out impairment of cell viability. The 
differences in the degree of ACBP knockdown may partly explain conflicting results in 
cell culture experiments. We obtained a 80% reduction of the ACBP protein, whereas 
other studies showed almost complete ACBP depletion. However, to investigate the 
putative gene regulatory function of ACBP it seems to be desirable to avoid negative 
pleiotrophic effects such as cytotoxicity and/ or apoptosis by ACBP knockdown. This 
was achieved in our study. Also expression data excluded the ACBP mediated 
induction of apoptosis-related genes since those were not over-estimated according 
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to GO classification of biological processes. Thus, siRNA-mediated depletion of 
ACBP in HepG2 cells is a suitable tool to study its gene regulatory function. Recent 
studies revealed even a function of ACBP in promoting and transmitting apoptosis at 
the level of protein-protein interaction. In this respect, suppression of ACBP 
ameliorated BH3 interacting domain death agonist (Bid)-induced mitochondrial 
damage and therefore prevented cell death (52). Solstad et al. (54) uncovered ACBP 
recently as phosphorylation target in the initial phase of apoptosis.  
 
Metabolic as well as transcriptional profiling data in ACBP-depleted cells and 
organisms are summarized in Tab. 3. Comprehensive studies were raised in yeast 
and comprised mainly parameters of lipid composition (14, 17, 49) and some gene 
expression data (16). Human cell culture studies focused on ACBPs role in adipocyte 
differentiation (35) and apoptosis induction (52). In this study, we identified 454 
genes to be differential expressed in ACBP-depleted HepG2 cells. Based on gene 
annotation enrichment analysis using DAVID and BSPE 20 ACBP-regulated genes 
were allocated towards cellular lipid metabolic processes. Remarkably, the vast 
amount of these lipogenic genes were transcriptionally repressed in ACBP-depleted 
HepG2 cells, whereas 6 of these down-regulated genes were classified to fatty acid 
metabolic processes. In accordance, we observed a significant reduced content of 
the fatty acids C16:0, C16:1 and C18:1n9 in ACBP exhausted HepG2 cells. Studies 
in yeast (49) and mice (27) confirmed the role of ACBP in fatty acid and acyl-CoA 
metabolism. Acb1p knockout yeast strain showed reduced total fatty acid content, 
especially of the very long chain FA C26:0 (17).  
 
The genes encoding FASN, ELOVL6 and PECR were transcriptional repressed in 
ACBP-exhausted HepG2 cells. This may explain the reduced fatty acid content in 
ACBP depleted cells, since all three genes encode key enzymes of fatty acid 
synthesis and elongation. FASN is a multifunctional protein, which has all enzymatic 
activities required for each cycle of fatty acid synthesis towards palmitic acid. 
ELOVL6 encodes for a protein catalyzing the elongation of palmitic acid towards long 
chain fatty acid. ELOVL is predicted to be important for tissue fatty acid composition 
and is also involved in obesity-induced insulin resistance (36, 39). PECR functions in 
fatty acid elongation, possesses high affinity to fatty acids with chain lengths up to 16 
carbons and shows marked expression in liver and kidney (8). Other genes that were 
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down-regulated following ACBP-depletion were FABP1 and ACOX1. FABP1 encodes 
for a liver-specific lipid binding protein, sequestering hydrophobic molecules including 
fatty acids, acyl-CoAs and cholesterol (20). ACOX1 encodes for a peroxisomal fatty-
acyl-CoA oxidase involved in ß-oxidation of long and very long chain fatty acid. 
Interestingly, ACOX1 was documented to interact with ACBP in a yeast-two-hybrid 
map of Drosophila melanogaster (19). Taken together, the obtained data suggest 
transcriptional repression of general fatty biosynthesis and elongation. This is 
supported by fatty acid profiles assessed in our ACBP knockdown HepG2 cells as 
well in Acb1p knockout yeast (49).  
 
The GPAM gene was also repressed in ACBP knockdown cells. GPAM encodes a 
key enzyme in phospholipid synthesis catalyzing the acylation of glycerol-3-
phosphate to lysophosphatic acid. This suggested a pertubated function of 
phospholipid metabolism under ACBP knockdown. Supportively, the relative 
phospholipid content and its composition was shown to be reduced in Acb1p 
exhausted yeast (16). Another interesting finding of our study is that ACBP-depletion 
changes expression of five genes allocating to steroid metabolic processes. Four of 
these cholesterogenic genes were commonly repressed. These included the two 
rate-limiting enzymes HMGCS1 and HMGCR as well as the more down-stream 
acting IDI1 and LSS. ACAT2 is involved in cholesterol esterification and was up-
regulated. The fact, that not all genes of cholesterol metabolism were differential 
regulated was also observed by others (10). Former studies in steroidogenic cells 
and tissues uncovered the involvement of ACBP in mitochondrial cholesterol up-take 
and conversion towards pregnenolone via the interaction with the peripheral-type 
benzodiazepine receptor (PBR) (2, 4). In consideration of current data, depletion of 
ACBP may lead to low cholesterol level thereby interfering also with steroid hormone 
synthesis. Low cholesterol synthesis might also contribute to disturbed membrane 
assembly and organization (17). Recent studies have already shown fragmented 
vacuoles in yeast lacking the cholesterol equivalent ergosterol (28). Moreover, a 
disturbed vesicular trafficking was observed in Acb1p-exhausted yeast (14, 17). 
Gene expression profiling in this yeast cells showed a repression the cytochrome 
P450 lanosterol 14a-demethylase which participates in the ergosterol biosynthesis 
pathway (16). Together, ACBP may have a conserved gene regulatory function in 
cholesterol/ ergosterol biosynthesis.  
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A number of transcription factors are known to substantially regulate key genes of the 
lipid metabolism. In the context of our study, the sterol regulatory element-binding 
proteins 1a and 2 (SREBP) are of special interest (1, 11, 50) because they regulate 
most of the genes depicted in Fig. 3. Thus, an interaction between ACBP and 
SREBP is considerable but has to be tested in future experiments by using promoter-
reporter assays, for example. In silico promoter analysis of the identified 20 ACBP 
target genes allocating to cellular lipid metabolic processes revealed that 16 genes 
possess a putative binding site for EGR1. Interestingly, the EGR1 gene itself was 
transcriptional repressed in ACBP exhausted HepG2 cells. The precise role of EGR1 
in ACBP-mediated suppression of target genes remains open but seems to be a 
promising approach to unravel the gene regulatory function of ACBP. 
 
In conclusion, genome-wide expression profiling in HepG2 cells under ACBP 
knockdown revealed a gene regulatory function of human ACBP in cholesterol and 
fatty acid biosynthesis. This effect seems to be translated into relevant metabolites. 
Moreover, the identified 454 ACBP regulated transcripts may present a first reference 
for further studies to define the ACBP regulon in mammalian cells.  
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Figures 
 
Fig.1. Repression of ACBP transcript- (A) and protein- (B) levels after siRNA 
transfection.  
HepG2 cells were transfected with 100 nmol/L of ACBP specific siRNA1, siRNA2 or 
scrambled siRNA as negative control. A) For qRT-PCR RNA was isolated after 24, 
36 and 48 h of transfection. Expression data are relative to HPRT1 as housekeeping 
gene and presented as mean ± SD (*p<0.05; n=2-4). B) Samples for western blot 
analyses were generated 72 h post-transfection. Beta-actin served as loading 
control. A representative immunoblot is depicted.  
 
Fig.2. Effects of ACBP knock-down on cell viability (A) and induction of 
apoptosis (B) 
HepG2 cells were transfected with 100nmol/L of ACBP specific siRNAs1, siRNA2 or 
control siRNAs against lamin A/C, cyclophilin B and scrambled siRNA for 72 h. 
Cytotoxicity and induction of apoptosis were determined by chemiluminescent 
measurement. Camptothecin (5µmol/L) was incubated for 16 h as a pro-apoptotic 
agent. Mock control cells were only incubated with transfection reagent. Data are 
represented relative to scrambled siRNA as mean ± SD (*p <0.001; n=4-5).  
 
Fig.3. Catalyzed reactions of regulated target genes allocated to cellular lipid 
metabolism and the involvement of human ACBP 
Human ACBP in involved in overall acyl-CoA metabolism. RNAi-mediated ACBP 
depletion resulted in down-regulation of rate-limiting enzymes of fatty acid, 
glycerolipid as well as cholesterol metabolism. ACBPs impact on gene regulation is 
assumed based on its nuclear localization. Attention was particularly given to 
regulated genes connected to acyl-CoA metabolism.  
G3P, glycerol-3-phosphate; LA, lysophosphatic acid; CE, cholesterol ester 
 
Fig.4. Effect of ACBP depletion in HepG2 cells on fatty acid content 
HepG2 cells were transfected with 100nmol/L ACBP specific siRNA1 and scrambled 
control siRNA. Fatty acid content was assessed 72 h post-transfection by gas 
chromatography as described in Material & Methods. Data are presented as mean ± 
SD (n=3; *p<0.05). 
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Tables 
 
Table 1. Gene Ontology classification of significant regulated genes in ACBP-
depleted HepG2 cells according biological processes and molecular function  
 
Table 2. ACBP regulated genes allocating to the GO term cellular lipid 
metabolic process and verification by qRT-PCR 
 
Table 3. Metabolic and transcriptional profiling studies conducted in ACBP-
depleted cells and organisms 
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Figure 3 
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Table 1 
 Gene count p-value Benjamini1 
GO term biological process    
Anatomical structure development 92 2.5E-6 4.1E-4 
Regulation of biological process 169 4.6E-6 3.8E-4 
Multicellular organismal development 97 5.2E-5 2.8E-4 
Cell cycle 47 1.2E-5 4.7E-4 
Cell development 59 1.6E-5 5.1E-4 
Regulation of cellular processes 156 2.3E-5 6.2E-4 
Cellular developmental process 77 4.2E-5 9.8E-4 
Cellular component organization and biogenesis 102 1.6E-4 3.2E-3 
Death 41 2.0E-4 3.6E-3 
Anatomical structure morphogenesis 49 8.0E-4 1.3E-2 
Cell cycle process 36 8.0E-4 1.2E-2 
Regulation of molecular function 27 3.4E-3 4.5E-2 
    
GO term molecular function    
Protein binding 256 2.2E-13 2.5E-11 
Transcription cofactor activity 19 9.7E-4 5.4E-2 
Transmembrane transport 43 1.3E-3 4.7E-2 
1
 p-value after Benjamini-Hochberg correction for multiple comparison  
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Table 2 
 
Gene ID Gene symbol Gene description Fold change 
   
microarray Real-time 
RT-PCR 
8435 ACAT2a Acyl-CoA:cholesterol acyltransferase 2 +1.35±0.08 +1.31±0.30 
51 ACOX1b, i acyl-Coenzyme A oxidase 1, palmitoyl -1.35±0.09  
972 CD74b, f CD74 molecule, major histocompatibility complex, class II invariant chain +1.41±0.05  
55907 CMASf, g cytidine monophosphate N-acetylneuraminic acid synthetase -1.33±0.12  
4051 CYP4F3b cytochrome P450, family 4, subfamily F, polypeptide 3 +1.32±0.08  
1958 EGR1k early growth response 1 -1.67±0.33 -1.62±0.09 
79071 ELOVL6b, f ELOVL family member 6, elongation of long chain fatty acids (FEN1/Elo2, 
SUR4/Elo3-like, yeast) 
-1.34±0.02  
2168 FABP1b fatty acid binding protein 1, liver -1.39±0.03  
2194 FASNb, f fatty acid synthase -1.40±0.01 -1.31±0.21 
57678 GPAMc, f glycerol-3-phosphate acyltransferase, mitochondrial -1.45±0.13 -1.37±0.13 
3155 HMGCLk 3-hydroxy-3-methylglutaryl-Coenzyme A lyase +1.33±0.03 +1.27±0.51 
3156 HMGCRa, e, f 3-hydroxy-3-methylglutaryl-Coenzyme A reductase -1.36±0.09 -1.39±0.25 
3157 HMGCS1a, e,f 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) -1.60±0.10 -1.56±0.14 
3422 IDI1a, e, f isopentenyl-diphosphate delta isomerase 1 -1.32±0.07 -1.23±0.20 
3612 IMPA1c, f inositol(myo)-1(or 4)-monophosphatase 1 -1.50±0.16  
4047 LSSa, f lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) -1.37±0.11 -1.11±0.33 
55825 PECRb, f peroxisomal trans-2-enoyl-CoA reductase -1.53±0.01 -1.49±0.09 
80339 PNPLA3d, i, j patatin-like phospholipase domain containing 3 -1.36±0.21  
5565 PRKAB2b, f protein kinase, AMP-activated, beta 2 non-catalytic subunit -1.48±0.08  
51109 RDH11e retinol dehydrogenase 11 (all-trans/9-cis/11-cis) -1.35±0.03  
81846 SBF2h SET binding factor 2 +1.33±0.14  
10402 ST3GAL6c ST3 beta-galactoside alpha-2,3-sialyltransferase 6 -1.39±0.08  
 
 32 
Gene expression profiling was performed 72 h after ACBP siRNA1 transfection in HepG2 cells. Data compromise 3 independent 
experiments. Selected target genes were verified with real-time RT-PCR. Data are present mean fold changes ± SD. GeneID is based 
on NCBI GenBank database. 
Sub-analysis of GO-term cellular lipid metabolic process 
a
 steroid metabolic process; b fatty acid metabolic process; c Membrane metabolic process; d neutral lipid metabolic process;  
e
 isoprenoid metabolic process; f lipid biosynthetic process;  
g
 lipopolysaccharide metabolic process; h lipid modification; i cellular lipid catabolic process ; j glycerolipid metabolic process,  
k
 literature-based allocation 
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Table 3 
 
Cell type/organism Essentiality Transcriptional and/or metabolic effects 
Yeast   
Schjerling et al. 1996 no growth rate↓; C18:0-CoA↑; ∆9-desaturase (OLE-1) expression↑; FA-composition ↔, FA-content ↓ 
Gaigg et al. 2001 no C18:0-CoA ↑; phospholipids ↔; C26:0-CoA ↓; sphingolipids ↓; perturbed plasma membrane structure; 
vesicle accumulation,; Elo1/2/3p expression ↔; OLE-1 expression ↑ 
Faergeman et al. 2004 no ceramide ↓; altered vacuole morphology & assembly; phospholipid composition altered  
Feddersen et al. 2007 no 134 differential expressed genes (44↓, 90↓) induction of FA-; phospholipid-; glycolysis-synthesis and 
stress response related genes; phospholipid composition altered 
Cell culture 
  
this study 
HepG2 cells 
no no morphological changes; no apoptosis & cytoxicity; 454 differential expressed genes (256 ↓, 196↑), 
repression of rate-limiting genes of FA-synthesis, glycerolipid and cholesterol synthesis, FA-content ↓ 
Boujrad et al. 1993 
MA-10 Leydig cells 
no hormone-stimulated steroid hormone synthesis ↓ 
Mandrup et al. 1998 
3T3L1 fibroblasts 
no lipid accumulation ↓; adipocyte differentiation ↓; PPARγ, C/EBPα expression ↓; expression of adipogenic 
genes ↓ 
Faergeman et al. 2002  
HeLa, HepG2, Chang-
cells 
yes growth arrest, detachment of cells, early apoptosis induction, cell death 
Shulga et al. 2003  
HeLa 
no prevention of apoptosis, t-Bid-induced activation of mitochondrial µ-calpain ↓ 
other   
Milne et al. 2001 
Trypanosoma brucei 
yes cell death  
Lee et al. 2007  
mouse 
no sebocyte hyperplasia, sparse, matted hair, abnormal hair lipid profile, liver lipids ↔ 
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Abstract 
The acyl-CoA binding protein (ACBP) is an ubiquitary expressed multi-functional protein 
which regulates basic cellular functions such as fatty acid and steroid metabolism. Since 
ACBP is described to interact with the transcription factor hepatocyte nuclear factor 4 
alpha (HNF-4α), we investigated the role of human ACBP on transcriptional regulation 
of the putative HNF-4α target gene HMG-CoA synthase 1 (HMGCS1). As shown by 
promoter-reporter assays ACBP represses the HNF-4α-induced activity of a 617bp 
HMGCS1 promoter fragment by approximately 80% in HepG2 cells as well as in non-
endodermal HeLa cells devoid of HNF-4α. Interestingly, reporter assays without co-
transfection of HNF-4α revealed that ACBP reduces the activity of the HMGCS1 
promoter by about 60 to 80% in both cell lines. Activities of 417bp and 317bp HMGCS1 
promoter fragments were 2.5 to 4 fold decreased by ACBP. Concordantly, the levels of 
HMGCS1-mRNA and -protein were diminished to 60% and 70% in ACBP-expressing 
HeLa cells, respectively. Additionally, ACBP reduces the promoter activity and the 
mRNA levels of the cholesterogenic HMG-CoA reductase (HMGCR). In conclusion, we 
provide evidence that ACBP is a transcriptional regulator of the HMGCS1 and HMGCR 
genes encoding rate-limiting enzymes of cholesterol synthesis.  
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Introduction 
 
Acyl-CoA binding protein (ACBP) is an essential member of lipid binding proteins 
that was originally isolated as diazepam binding inhibitor (DBI) from rat brain with its 
ability to displace diazepam from gamma aminobutyric acid receptors [1]. The 
ubiquitously expressed ACBP shows a high degree of structural and functional 
conservation [2] and exerts versatile cell and tissue type-specific functions as: 
regulation of glucose-induced insulin secretion from pancreatic beta cells [3,4], 
modulation of cell proliferation in testicular Leydig cells [5], modulation of monocyte 
mediated inflammation [6,7], antibacterial properties [8], release of cholecystokinin from 
intestine [9] or stimulation of steroidogenesis [10-12].  
The abundance of ACBP in energy-consuming cells and tissues, such as adrenal cortex 
or testis, and its high affinity towards medium- and long chain acyl-CoAs, support 
ACBPs crucial role in fatty acid metabolism [13-15]. Besides sequestering activated 
fatty acids, ACBP is particularly involved in the protection and pool formation of acyl-
CoAs [16,17] and their donation to cell organelles, membranes and special enzyme 
systems [16,18-22]. Beside being intermediates and substrates in metabolism acyl-
CoAs are regulators and signaling molecules, affecting a number of cellular functions 
including activity of ion channels, ion pumps or enzymes [reviewed in [23]]. Moreover, 
they are described to impact signal transduction pathways as well as gene expression 
[24]. The gene-regulatory function of acyl-CoAs is based on their ability to act as 
agonistic or even antagonistic ligands for a number of nuclear factors. This was in detail 
shown for the endodermal derived hepatocyte nuclear factor (HNF)-4 alpha [25], 
originally regarded as orphan nuclear factor, but also for peroxisome proliferator-
activated receptors (PPARs) [26]. In this respect, ACBP impacts the availability and 
accessibility of acyl-CoAs not only for general metabolism but also for gene regulatory 
properties. Recently, expression profiling confirmed the importance of acyl-CoA ligand 
binding for the induction of transcriptional changes in Acb1p-depleted yeast [27]. A 
putative gene regulatory function of ACBP is moreover implicated, as ACBP directly 
interacted with HNF-4α, thereby activating the transcription of genes involved in lipid 
and glucose metabolism [28]. In keeping with this, gene expression analysis revealed 
numerous genes of fatty acid, phospholipid as well as glycerol synthesis to be up-
regulated in Acb1p-depleted yeast [27].  
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Until today data about the impact of ACBP on cholesterol metabolism are limited 
to steroidogenic cells and tissues. ACBP and its processing products 
trikontatetraneuropeptide (TTN) and octadecaneuropeptide (ODN) are described to 
enhance steroidogenesis by activating the transport of cholesterol towards the inner 
mitochondrial membrane, a process thought to be mediated by the interaction with 
peripheral-type benzodiazepine receptor (PBR) [11,29]. In the present study we 
analyzed the impact of ACBP on two key rate-limiting enzymes, HMG-CoA synthase 
(HMGCS1) and HMG-CoA reductase (HMGCR), in two different human cell lines by an 
ACBP overexpression approach.  
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Material and Methods  
 
Cell culture and transient transfection  
Human hepatocellular HepG2 and cervical HeLa cells were purchased from the 
German Resource Centre for Biological Material (DSMZ, Braunschweig, Germany). 
HepG2 cells were maintained in RPMI + 1% Glutamax (Invitrogen, Carlsbad, USA) 
supplemented with 10% fetal calf serum (FCS). HeLa cells obtained MEM media 
(Invitrogen, Carlsbad, USA) containing 10% FCS and 1% non-essential amino acids 
(PAA, Cölbe, Germany). Cells were grown until preconfluent density in a humified 5% 
CO2/95% air atmosphere at 37°C. Media was changed every 2 days and cells were 
passaged with 0.25% trypsin in PBS (HepG2) and 0.05% trypsin/0.02% EDTA solution.  
Transient transfections were performed with FuGene6 transfection reagent according to 
the manufacturer’s protocol (Roche, Basel, Switzerland). For qRT-PCR and 
immunodetection HepG2 (1.5x105) and HeLa (4x104) cells were plated in 24-well 
dishes. After 24 h, cells were transfected with 800 ng ACBP-V5 expression plasmid in 
6:1 ratio of FuGene6 reagent (µl) to DNA (µg). For ChIP analysis, 1x106 HeLa cells 
were seeded on 10 cm dishes (4 dishes per condition). Cells were transfected at 50% 
confluence with 15 µg ACBP-V5 expression plasmid in 3:1 ratio of FuGene6 reagent 
(µl) to DNA (µg) for 24 h.  
 
Plasmids 
All plasmids were produced using cloning based on PCR and Gateway 
technology (Invitrogen, Carlsbad, USA). Preparation of the human HNF-4α expression 
plasmid is described by Klapper et al. [30]. Human ACBP isoform 1A (NM_001079862, 
NP_001073331) including stop-codon (ACBP) was cloned into the expression vector 
pcDEST40. To allow C-terminal fusion with V5 (ACBP-V5), site-directed mutagenesis 
(Stratagene, La Jolla, USA) was performed according to the manufacturer’s protocol. 
Mutagenic primers were as follows (mutated sites underlined): for: 5’- 
AAAAATACGGGATAGGAAAGGGTGGGCG-3’ and rev: 5’-
CGCCCACCCTTTCCTATCCCGTATTTTT-3. Promoter fragments -617/-1 bp, -417/-1 
bp, -317/-1 bp, and -217/-1 bp of human HMG-CoA synthase 1 (HMGCS1, NM_002130) 
and promoter fragment -528/-1 bp of human HMG-CoA reductase (HMGCR, 
NM_000859) were cloned into pSEAP-basic vector (Promega, Mannheim, Germany), 
containing cassette C of the Gateway vector conversion system. Positions are given 
 7 
relative to transcription start sites. PCR-primers for cloning of promoter fragments are 
depicted in Tab.1. All plasmids were approved by sequencing.  
 
SEAP reporter gene assay 
Promoter analyses were performed using secretory alkaline phosphatase (SEAP) 
as reporter gene. HepG2 (3x104) and HeLa (5x103) cells were seeded in 96-well plate 
format and cultured for 24 h. Cells were transfected using FuGene6 transfection reagent 
(Roche, Basel, Switzerland) after manufacturer’s instruction in 6:1 ratio of FuGene6 to 
DNA with 60 ng of promoter construct, 37.6 ng ACBP/ACBP-V5 expression plasmid and 
2.4 ng of luciferase-containing pGl3 control plasmid (Promega, Madison, USA) as 
transfection efficiency control. For transfection with human HNF-4α, 50 ng promoter 
plasmid, 31.5 ng ACBP expression plasmid, 16 ng HNF-4α and 2.0 ng pGl3 were 
accordingly transfected. The total amount of 100 ng plasmid per well was adjusted with 
empty pcDEST40 expression vector. Transfection of pSEAP2-basic without promoter 
fragment was used as negative control for background correction.  
After 48 h media was removed and frozen at -20°C until measurement of SEAP activity 
with Great EscAPe SEAP chemiluminescence detection kit (BD Bioscience Clontech, 
Palo Alto, USA). Cells were washed with 1x PBS, lysed by the addition of Glo Lysis 
Buffer (1x) and kept at -20°C (Promega, Madison, USA). Luciferase activity was 
measured with commercial Bright-Glow Assay Reagent (Promega, Madison, USA) after 
manufacturer’s protocol. Chemiluminescence measurement was performed on 96-well 
flat-bottom opaque microplate in GloMax™ microplate luminometer (Turner Biosystems, 
Sunnyvale, USA). Each experiment was performed at least 3 times in triplicate. 
 
Real-time RT-PCR (TaqMan®) 
Quantification of HMGCS1 and HMGCR mRNA level was performed with 
quantitative RT-PCR based on TaqMan® principle. In brief, total RNA was isolated after 
12, 24 and 48 h of transfection using RNeasy kit (Qiagen, Hilden, Germany). cDNA was 
prepared using iScript cDNA synthesis kit (BioRad Laboratories, Hercules, USA). QRT-
PCR was done in triplicate in at least three independent cell culture experiments using 
ABI Prism 7000 Sequence Detection System (PE Applied Biosystems, Foster City, 
USA). HMGCS1 and HMGCR gene expression assays were commercially available 
from PE ABI. Quantification was based on comparative ∆Ct method using hypoxanthine 
phosphoribosyl-tranferase 1 (HPRT1) as endogenous control.  
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Two negative controls (-RT/-RNA template) were included to detect possible 
contamination. PCR was performed according to the manufacture’s protocol (PE 
Applied Biosystems, Foster City, USA). 
 
Immunodetection of ACBP and HMGCS1  
Transient transfection of HeLa cells was performed as described. After 72 h cells 
were harvested and lysed in 1x reaction buffer (5 mmol/L colic acid, 0.1% Triton X-100 
in PBS, pH7.4) incubated for 20 min at 4°C and subsequently sonicated. Protein 
concentration was measured with BCA kit (Pierce, Rockford, USA) according 
manufacturer’s instruction. Reaction buffer (1x) was used as lysis buffer for subsequent 
cholesterol measurement [31].  
Whole cell extracts were suspended in NuPage LDS sample buffer (Invitrogen, 
Carlsbad, USA) and denaturated at 70°C for 10 min. Samples were loaded on 12 % 
polyacrylamide gel and transferred by electroblotting to a PVDF membrane (Roth, 
Karlsruhe, Germany). ACBP specific polyclonal antibody (ACBP_total) was raised in 
rabbit by Eurogentec (Seraing, Belgium) after immunization of specific antigen 
(58AWNELKGTSKEDAMK72) mapping exon 3 and 4 of ACBP 1A isoform 
(NP_001073331).  
For immunodetection membranes were probed with specific primary antibodies Ab 
ACBP_total (1:2000), HMG-CoA synthase 1 (1:1000, Santa Cruz Biotechnology, Santa 
Cruz, USA) or actin goat polyclonal antibody (1:1000, Santa Cruz Biotechnology, Santa 
Cruz, USA) followed by horseradish peroxidase-coupled secondary antibody (1:10.000). 
Immunoreactive bands were visualized using chemiluminescent substrate ChemiGlow 
and quantified with Alpha Ease FC software (Alphaimager HP, AlphaInnotech, San 
Leandro, USA).  
 
Cholesterol measurement 
Cellular cholesterol content was measured by Amplex® Red Cholesterol Assay 
(Molecular Probes/Invitrogen, Carlsbad, USA). Protein concentration of the samples 
was measured with BCA kit according manufacturers instructions (Pierce, Rockford, 
USA). Cellular cholesterol is oxidised to H2O2 and detected by fluorescent 
measurement using 10-acetyl-3, 7-dihydrophenoxazine (Amplex Red reagent) with 
Infinite F500 plate reader (λEx= 535nm; λEm=590 nm, Tecan Crailsheim, Germany). 
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Results are expressed as cholesterol concentration (µg/ml) in corresponding samples of 
10 µg protein absolute. Each sample was measured in duplicate. 
 
Chromatin immunoprecipitation  
ChIP assay was performed using ChIP-ITTM Express enzymatic kit (Active Motif, 
Carlsbad, USA) after manufacturer’s protocol. Protein/DNA complexes were fixed with 
formaldehyde and chromatin was sheared enzymatically into uniform fragments of 200-
1000 bp size. Specific ACBP/DNA complexes were precipitated overnight using 3 µg of 
ACBP_total primary antibody. To control efficiency of chromatin immunoprecipitation 
and to exclude non-specific DNA binding, 3 µg of rabbit IgG antibody (Santa Cruz 
Biotechnology, Santa Cruz, USA) was used in parallel. Chromatin was isolated 
according manufacturer’s instructions and stored at -80°C until PCR analysis.  
Chromatin was subjected to PCR analysis to amplify putative HMGCS1 promoter 
regions subjected to ACBP interaction. Primers for amplification of 207 bp HMGCS1 
promoter fragment were as follows: forward 5’-TGGCCCGCATCTCCTCTCAC-3’ and 
reverse 5’-GCTAGGATTTTCCCTCGTG -3. Amplification was carried out under 
following cycling conditions: 3 min at 94°C, 5 cycles with 30s at 94°C, 30s at 64°C, 30 s 
at 72°C, 5 cycles with 30s at 94°C, 30s at 62°C, 30 s at 72°C, followed by 30 cycles of 
30s at 94°C, 30s at 60°C, 30 s at 72°C and final extension at 72°C for 10 min. As 
negative control genomic primers for GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) were used (F: 5’-TCCATGACAACTTTGGTATCGTGG-3’, R: 5’-
GACGCCTGCTT-CACCACCTTCT-3’. Amplification of chromatin prior to 
immunoprecipitation was used as an input control. ChIP was performed in two 
independent experiments comprising independent cell passages. Chromatin of each 
experiment was precipitated twice with appropriate antibody.  
 
Statistical analysis 
Statistical analysis was performed with GraphPad Prism4 (Graphpad software, 
Inc., San Diego, USA) using 2-tailed Student´s paired t-test. All values were expressed 
as mean ± SD. Significant differences were considered for P values less than 0.05. 
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Results  
 
ACBP represses the HNF-4α-induced promoter activity of HMGCS1 
ACBP is described to interact with HNF-4α [28], a transcription factor that 
controls glucose, fatty acid and cholesterol metabolism [32]. Because ACBP is also 
described as putative regulator of cholesterol metabolism [11,29], we investigated the 
impact of HNF-4α and ACBP on the promoter activity of HMGCS1. This gene encodes 
a rate-limiting enzyme of cholesterol synthesis and contains a putative HNF-4α binding 
site within its promoter region at position -274 to -249. We performed promoter-reporter 
assays with a functional 617bp segment of the HMGCS1 promoter. This HMGCS1-
SEAP construct showed an about 60-fold higher activity in comparison to the negative 
control plasmid pSEAP-basic (data not shown) and could therefore be classified as 
moderate promoter. As shown in Fig. 1, HNF-4α led to 2-fold activation of basal 
HMGCS1 promoter activity in human liver HepG2 cells. Interestingly, co-transfection of 
a V5-tagged human ACBP cDNA (ACBP-V5) together with HNF-4α strongly decreased 
the HNF-4α effect by a factor of 5 (Fig. 1). In comparison to HepG2 cells which contain 
endogenous HNF-4α, HeLa cells show no HNF-4α expression [33]. Here, the HNF-4α-
induced activity of the HMGCS1 promoter is decreased by ACBP-V5 to nearly 25% (Fig. 
1). Thus, we found evidence in two different cell lines that ACBP represses the HNF-4α-
induced promoter activity of the HMGCS1 gene.  
 
ACBP is a negative transcriptional regulator of HMGCS1 
Based on our findings we speculate that ACBP may function as a negative 
transcriptional regulator of HMGCS1. To test this, ACBP-mediated activity of the 
HMGCS1 promoter was determined without co-transfection of HNF-4α. As depicted in 
Fig. 2A, the ACBP-V5 fusion protein significantly repressed the activity of the 617bp 
HMGCS1 promoter fragment by 63% and 83% in HepG2 and HeLa cells, respectively. 
In order to exclude possible artifacts of the V5-tag, a plasmid encoding native ACBP 
was also used. As shown in Fig. 2A, promoter activity of HMGCS1 was strongly 
repressed by native ACBP to 20% in HepG2 and to 25% in HeLa cells.  
In order to provide further evidence for repressive effect of ACBP on HMGCS1 
promoter activity, we performed reporter gene assays using -417/-1, -317/-1, and -217/-
1 bp fragments of the HMGCS1 promoter. Since the shortest 217bp fragment showed 
only poor activity in HepG2 and HeLa cells, an ACBP-mediated repressive effect would 
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hardly be detectable. Therefore this fragment was excluded from ongoing experiments. 
In comparison to the -617/-1 HMGCS1 promoter fragment, -417/-1 and -317/-1 
constructs showed 50-70% activity in both cell lines. As shown in Fig. 2B, these shorter 
HMGCS1 promoter fragments respond strongly to ACBP-V5. For the -417/-1 construct, 
a repressive effect to 27% and 21% could be observed in HepG2 and HeLa cells, 
respectively. ACBP-V5 mediated decrease of HMGCS1 -317/-1 promoter activity was 
62% in HepG2 cells and 47% in HeLa cells. Together, these findings show that ACBP 
represses the activity of different HMGCS1 promoter constructs.  
 
ACBP decreases the levels of HMGCS1-mRNA and -protein 
To analyze if the repressive effect of ACBP on HMGCS1 promoter could also be 
observed at the transcript level, we quantified HMGCS1 mRNA levels in HepG2 and 
HeLa cells 24 h and 48 h after transfection of ACBP-V5. As shown in Fig. 3A, transcript 
levels of HMGCS1 did not change significantly in dependence of ACBP expression and 
time in HepG2 cells. In HeLa cells mRNA levels of HMGCS1 were considerably 
diminished to 64% (p=0.064) and 70% (p=0.057) 24 h and 48 h after ACBP-V5 
transfection, respectively.  
We further investigated if ACBP decrease HMGCS1 at protein level. For this 
purpose, we analyzed HMGCS1 protein levels in HeLa cells expressing ACBP-V5. 
Expression rate of the 14 kDa V5-tagged ACBP was also assessed and quantification 
was based on densitometric measurement. Based on a 6-fold enrichment of V5-tagged 
ACBP compared to endogenous ACBP levels (Fig.3B, upper panel) we observed 
reduced HMGCS1 protein levels to 70% compared to control cells after 48 h (Fig. 3B, 
middle panel). Together, mRNA as well as protein level of HMGCS1 were negatively 
regulated by ACBP. 
 
The activity of a HMGCR promoter and the HMGCR mRNA is reduced by ACBP 
In order to extend our analysis regarding ACBP as a transcriptional regulator, we 
investigated the HMGCR gene, which encodes the second rate-limiting enzyme in 
cholesterol synthesis. As shown in Fig. 4, ACBP-V5 reduces the activity of a 528bp 
promoter fragment of HMGCR by 68% and 84% in HepG2 as well as in HeLa cells. The 
HMGCR-mRNA is not substantially affected by ACBP-V5 in HepG2 cells. However, in 
HeLa cells ACBP decreases HMGCR mRNA levels significantly to 56% after 24 h. 
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Distinct HMGCR mRNA repression was not observed 48 h post-transfection. Thus, 
ACBP is also a negative transcriptional regulator of HMGCR.  
 
No impact of ACBP on cellular cholesterol level  
Given that ACBP-V5 represses HMGCS1 and HMGCR at transcriptional level, 
we investigated the impact of ACBP on cholesterol levels in HeLa cells. As shown in 
Tab. 2, 48 h and 72 h after ACBP-V5 transfection we observed no difference in total 
cholesterol levels between control cells and cells expressing ACBP-V5.  
 
Chromatin immunoprecipitation revealed no direct interaction of ACBP with 
HMGCS1 promoter 
To identify a possible direct binding of ACBP to HMGCS1 promoter we 
performed chromatin immunoprecipitation in HeLa cells transfected with ACBP-V5 for 
24 h. Precipitated DNA was subjected to PCR analyses using primers to amplify a 207 
bp fragment corresponding to the HMGCS1 promoter sequence -418/-212. As depicted 
in Fig. 5, specific amplification of -418/-212 bp HMGCS1 promoter fragment was 
obtained in the presence of ACBP antibody. Amplified 207 bp HMGCS1 promoter 
fragment was less abundant when precipitated with non-specific IgG antibody. PCR 
analysis with human GAPDH primer set showed enrichment of 306 bp GAPDH 
amplicon with ACBP antibody precipitated chromatin when compared with IgG 
precipitated chromatin. Enrichment of control GAPDH PCR product in ACBP 
precipitated chromatin samples indicates unspecific binding of chromatin towards 
polyclonal ACBP antibody. 
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Discussion 
ACBP is a multi-functional protein which is involved in basic cell metabolism such 
as fatty acid metabolism and steroidogenesis. ACBP functions also in highly specialized 
and regulated processes such as insulin [3,4] and cholecystokinin secretion [9]. The 
best established role of ACBP is its ability to bind long-chain fatty acid-coenzyme A 
esters (acyl-CoAs). ACBP acts as a cellular acyl-CoA transporter and pool former. 
Beside being intermediates of fatty acid biosynthesis and consumption, acyl-CoAs are 
described as regulatory and signaling molecules involved in gene expression and cell 
metabolism [23]. Therefore, ACBP is an important regulator protein for cell signaling 
and gene regulation. It is also known that ACBP is involved in steroid biosynthesis by 
increasing cholesterol transport to mitochondria [34]. Here we show by promoter-
reporter assays in two different cell lines that ACBP decreases the transcription of the 
HMGCS1 and HMGCR gene encoding the initial enzymes of cholesterol biosynthesis. 
The increased ACBP expression was highly comparable to liver ACBP level achieved in 
transgenic rats [35]. The HMGCS1 catalyzes the condensation of acetyl-CoA and 
acetoacetyl-CoA towards 3-hydroxy-3-methyl-glutaryl (HMG)-CoA. HMGCR catalyzes 
subsequently the conversion of HMG-CoA to mevalonate. In comparison to significantly 
decreased promoter activities and mRNA levels of HMGCS1, western analyses 
revealed only a slight reduction in protein expression level to 70%. Analogous to this 
weak down-regulation no changes in cholesterol levels were observed. These findings 
reflect the complex regulation of the cholesterol biosynthesis, a pathway that comprises 
numerous stages with counteracting regulatory mechanisms. In general, cholesterol 
synthesis is tightly and complex controlled in order to meet cellular cholesterol demands 
[36]. Thus, versatile transcriptional and post-transcriptional mechanisms are employed. 
These include not only feed-back control of target gene transcription and translation but 
also allosteric control of HMGCS1 and HMGCR activity as well as cholesterol uptake 
[37]. Regarding cholesterol levels, those regulatory mechanisms might compensate the 
repressing effect of ACBP on the transcription of HMGCS1 and HMGCR. Thus, it would 
be of interest to measure metabolites, for example HMG-CoA or mevalonate, in closer 
vicinity to the repressed HMGCS1 and HMGCR.  
 
To get insight into the precise function of ACBP as a transcriptional regulator we 
performed ChIP analyses using the promoter fragment which showed the strongest 
suppressive effect of ACBP on HMGCS1. This approach revealed no genomic sites that 
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were directly bound by ACBP. Therefore, ACBP seems not to be a transcription factor. 
A way in which ACBP could regulate the expression of HMGCS1 and HMGCR is 
physical interaction with HNF-4α. Petrescu et al. (2003) reported direct interaction of 
ACBP with HNF-4α as well as a stimulatory effect of ACBP on HNF-4α mediated 
transactivation of an apolipoprotein B (ApoB) promoter construct [28]. Contrarily to this 
stimulatory effect, ACBP lowered the HNF-4α induced activity of the HMGCS1 
promoter. Further, ACBP repressed the activity of the HMGCS1 and HMGCR promoter 
fragments in HeLa cells. This non-endodermal cell line does not express HNF-4α [33]. 
Thus, a profound function of HNF-4α on ACBP mediated transcriptional repression of 
HMGCS1 and HMGCR is not presumable. A study by Misawa et al. (2003) confirmed 
interaction of sterol-responsive element binding protein (SREBP)-2 with HNF-4α to 
effectively activate cholesterogenic genes, including low density lipoprotein receptor 
(LDLR), sterol isomerase (SI) and HMGCS1 [38]. Here we show that HNF-4α alone 
transactivates HMGCS1 promoter under sterol-independent conditions. This may 
provide further insights into the complex regulation of cholesterol synthesis pathway. 
 
In principal, SREBP-2 is another transcription factor which may interact with 
ACBP. Supportively, our HMGCS1 promoter fragments contain two functional sterol 
regulatory element (SRE)-like motifs within the region -290 to -281 and -308 to -299, 
which are also conserved in the hamster HMGCS1 gene [39,40]. SREBPs require co-
regulatory proteins such as CCAAT-binding factor/nuclear factor-Y (CBF/NF-Y) or the 
universal transcription factor SP-1 the for their gene regulatory function. In preliminary 
experiments, we tested possible interaction between SREBP-2 and ACBP using 
HMGCS1 promoter constructs in HeLa cells. SREBP-2 could not abolish ACBP 
repressive effect on basal HMGCS1 promoter activity suggesting no functional 
interaction.  
 
It has been shown that overexpression of ACBP increases cellular acyl-CoA 
content in yeast and mouse liver [17,41,42]. Acyl-CoAs are important ligands for several 
enzymes and are implicated in regulation of gene transcription [43,44]. In this context, 
the well known transcription factor PPARα, which interacts with the retinoid X receptor 
(RXR), is described to directly interact with acyl-CoAs [26] and may regulate HMGCS1. 
Competition of acyl-CoA binding by ACBP and PPARα might be one possible 
mechanism of the observed ACBP effect on HMGCS1. Interestingly, ACBP repressed 
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317 bp HMGCS1 promoter fragment less strongly in comparison to 417 bp promoter 
construct. Thus, ACBP might interfere with HMGCS1 promoter activity within the region 
-417 and -317. Promoter analysis applying Genomatix MatInspector 
(www.genomatix.de) revealed binding sites for various transcriptional regulators. A 
putative recognition site for vitamin D receptor/RXR heterodimers (VDR/RXR) was 
identified. Conditions of heterodimeric complex formation include the presence of the 
cholesterol-derived 1,25-dihydroxyvitamin D3 [45]. Taken together, the contribution of 
PPARα/RXR and/or VDR/RXR to the suppression of HMGCS1 by ACBP needs to be 
investigated in further studies.  
 
In conclusion, our findings indicate for the first time that ACBP regulates 
HMGCS1 and HMGCR, two enzymes in the initial steps of cholesterol biosynthesis. 
Further work is necessary to delineate the precise mechanisms by which ACBP 
represses HMGCS1 and HMGCR gene expression and consequently cholesterol 
synthesis.  
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Figure legends 
 
Figure 1 
HNF-4α induced HMGCS1 promoter activity was suppressed by ACBP in HepG2 
(A) and HeLa (B) cells. 
HepG2 and HeLa cells were transfected with HNF-4α alone or together with ACBP-V5 
expression plasmid producing the 14 kDa V5-tagged ACBP. SEAP activity was 
measured 48 h post-transfection and normalized to luciferase containing pGl3. Data are 
presented as mean ± SD (n=3; Student’s t-test). 
 
Figure 2 
Expression of ACBP suppressed the activity of basal 617bp HMGCS1 promoter 
(2A) and of 417bp and 317bp HMGCS1 promoter deletion fragments (2B) in HepG2 
and HeLa cells.  
(2A) Activity of basal 617bp HMGCS1 promoter was assessed in HepG2 (A) and HeLa 
(B) cells transiently transfected with both ACBP expression plasmids producing either 
the 14 kDa ACBP-V5 fusion protein or the native 10 kDa ACBP. (2B) Activity of 
truncated -417/-1 and -317/-1 HMGCS1 promoter fragments was analyzed in ACBP-V5 
expressing HepG2 (A) and HeLa (B) cells. SEAP activity was measured after 48 h and 
normalised to luciferase activity. Each experiment was performed in three independent 
cell passages in triplicate for each sample. Data are presented as mean ± SD. Student’s 
paired t-test (***p <0.0001, **p<0.001, *p<0.01).  
 
Figure 3 
Expression of ACBP decreased HMGCS1-mRNA and protein levels in HeLa cells. 
(3A) HepG2 (A) and HeLa (B) cells were transiently transfected with ACBP-V5 
expression plasmid for 24 h and 48 h. HMGCS1 transcript levels were measured by 
real-time RT-PCR. Data are presented as x-fold expression in comparison to control 
cells incubated only with FuGene6 (mean ± SD; n=3-4). The p-value is indicated. (3B) 
A representative Western blot shows 48 h post-transfection immunodetection of ACBP, 
HMGCS1 and ß-actin (loading control) in ACBP-overexpressing (ov) and in control (co) 
HeLa cells (1) indicates the detection of V5-tagged ACBP and (2) the level of HMGCS1 
in the transfectant.  
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Figure 4  
Expression of ACBP suppressed HMGCR in HeLa cells at the transcriptional 
level. 
HepG2 (A) and HeLa (B) cells were transiently transfected with ACBP-V5 expression 
plasmid (4A) HMGCR SEAP activity was measured after 48 h and normalized to 
luciferase activity. The results are presented as mean ± SD (n=4;***p<0.0001). (4B) 
HMGCR transcript levels were assessed by real-time RT-PCR 24 h and 48 h after 
ACBP-V5 expression. Data are presented as x-fold expression in comparison to control 
cells incubated only with FuGene6 (mean ± SD, n=3-4). The p-value is indicated. 
 
Figure 5 
Chromatin Immunoprecipitation revealed no direct binding of ACBP to HMGCS1 
regulatory DNA-sequences.  
Formaldehyde cross-linked chromatin was prepared from HeLa cells and 
immunoprecipitated with antibodies to ACBP and immunglobulin G (IgG) as negative 
control. PCR was performed with specific primers for the HMGCS1 promoter -418/-212 
and for GAPDH as a negative control. A sample representative of the total input 
chromatin (input DNA) was included in the PCR analysis. Lane 5 shows a PCR negative 
control. Transfection experiment was performed in duplicate each with 2 independent 
immunoprecipitations. M, 100 bp DNA marker  
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Table 1. Sequence of primers used for cloning of SEAP reporter gene constructs 
SEAP reporter gene constructs Sequence 5’→3’ 
HMGCS1 reporter gene constructs 
-617 bp forward GTATTCTGCTCCAATTTGC 
-417 bp forward GGCCCGCATCTCCTCTCAC 
-317 bp forward TCTCGTGCCACCTCACGTC 
-217 bp forward CCTAGCGAGTCATCGCCTC 
reverse primer AAGGGAGTGAGCCACGAAAGG 
HMGCR reporter gene construct 
-528 bp forward AGTTACAGGTTTGAGGTG 
reverse primer TACGCACGCTCGGAGCTGGA 
Forward primers contain the nucleotides CACC at 5’ end for Gateway cloning  
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Table 2. Total cholesterol levels did not change in HeLa cells transfected for 48 h and 
72 h with ACBP-V5 
 48 h  72 h 
    
ACBP-V5 1.61 ± 0.42 µg/ml  3.17 ± 1.12 µg/ml 
control 1.47 ± 0.92 µg/ml  2.85 ± 1.3 µg/ml 
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Figure 2 
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Figure3 
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Figure 4  
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